Ahahsyba

CENTER FOR DRUG EVALUATION AND
RESEARCH
APPLICATION NUMBER:
208398Orig1s000
MEDICAL REVIEW(S)
Clinical Review
Sheral S. Patel, M.D.
NDA 208398 – 505(b)(2)
VERMOXTM CHEWABLE (mebendazole 500 mg chewable tablets)
CLINICAL REVIEW
Application Type 505(b)(2)
Application Number(s) 208398
Priority or Standard Priority
Submit Date(s) 19 April 2016
Received Date(s) 19 April 2016
PDUFA Goal Date 19 October 2016
Division/Office Division of Anti-Infective Products
Office of Antimicrobial Products
Reviewer Name(s) Sheral S. Patel, M.D.
Review Completion Date 30 September 2016
Established Name Mebendazole 500 mg chewable tablets
(Proposed) Trade Name VERMOXTM CHEWABLE
Applicant Janssen Pharmaceuticals, Inc.
Formulation(s) Tablet, oral
Dosing Regimen Single oral dose
Applicant Proposed Anthelmintic indicated for the treatment of single or mixed
Indication(s)/Population(s) gastrointestinal infestations by Trichuris trichiura (whipworm);
Ascaris lumbricoides (large roundworm); and Ancylostoma
(b) (4)
duodenale
Adults and pediatrics (greater than 1 year of age)

Recommendation on Approval
Regulatory Action
Recommended Anthelmintic indicated for the treatment of gastrointestinal
Indication(s)/Population(s) infections by Trichuris trichiura (whipworm); Ascaris lumbricoides
(b) (4)
(large roundworm); and Ancylostoma duodenale
Adults and pediatrics (greater than 1 year of age)
CDER Clinical Review Template 2015 Edition 1

Reference ID: 3995807
Clinical Review
NDA 208398 – 505(b)(2)
Table of Contents
Glossary ........................................................................................................................................... 9
1 Executive Summary ............................................................................................................... 11

1.1. Product Introduction ...................................................................................................... 11
1.2. Conclusions on the Substantial Evidence of Effectiveness ............................................ 11
1.3. Benefit-Risk Assessment ................................................................................................ 11
2 Therapeutic Context .............................................................................................................. 17

2.1. Analysis of Condition ...................................................................................................... 17
2.2. Analysis of Current Treatment Options ......................................................................... 17
3 Regulatory Background ......................................................................................................... 18

3.1. U.S. Regulatory Actions and Marketing History ............................................................. 18
3.2. Summary of Presubmission/Submission Regulatory Activity ........................................ 18
3.3. Foreign Regulatory Actions and Marketing History ....................................................... 19
4 Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on

Efficacy and Safety................................................................................................................. 20
4.1. Office of Scientific Investigations (OSI) .......................................................................... 20
4.2. Product Quality .............................................................................................................. 20
4.3. Clinical Microbiology ...................................................................................................... 21
4.4. Nonclinical Pharmacology/Toxicology ........................................................................... 21
4.5. Clinical Pharmacology .................................................................................................... 22
4.5.1. Mechanism of Action .............................................................................................. 22
4.5.2. Pharmacodynamics ................................................................................................. 22
4.5.3. Pharmacokinetics .................................................................................................... 22
4.6. Devices and Companion Diagnostic Issues .................................................................... 24
4.7. Consumer Study Reviews ............................................................................................... 25
5 Sources of Clinical Data and Review Strategy ....................................................................... 25

5.1. Table of Clinical Studies.................................................................................................. 25
5.2. Review Strategy.............................................................................................................. 25

Clinical Review
NDA 208398 – 505(b)(2)
6 Review of Relevant Individual Trials Used to Support Efficacy ............................................. 26

6.1. MEBENDAZOLGAI3002 ................................................................................................... 26
6.1.1. Study Design............................................................................................................ 26
6.1.2. Study Results ........................................................................................................... 26
6.2. MEBENDAZOLGAI3003 ................................................................................................... 26
6.2.1. Study Design............................................................................................................ 26
6.2.2. Study Results ........................................................................................................... 30
7 Integrated Review of Effectiveness ....................................................................................... 33

7.1. Assessment of Efficacy Across Trials .............................................................................. 33
7.1.1. Primary Endpoints................................................................................................... 33
7.1.2. Secondary and Other Endpoints ............................................................................. 33
7.1.3. Subpopulations ....................................................................................................... 33
7.1.4. Dose and Dose-Response........................................................................................ 33
7.1.5. Onset, Duration, and Durability of Efficacy Effects ................................................ 33
7.2. Additional Efficacy Considerations................................................................................. 33
7.2.1. Considerations on Benefit in the Postmarket Setting - A. lumbricoides, T. trichiura
(b) (4)
Infections......................................... 33
7.2.2. Considerations on Benefit in the Postmarket Setting - Adults ............................... 37
7.2.3. Other Relevant Benefits – Mixed species infections .............................................. 38
7.3. Integrated Assessment of Effectiveness ........................................................................ 39
8 Review of Safety .................................................................................................................... 40

8.1. Safety Review Approach ................................................................................................ 40
8.2. Review of the Safety Database ...................................................................................... 41
8.2.1. Overall Exposure ..................................................................................................... 41
8.2.2. Relevant characteristics of the safety population .................................................. 41
8.2.3. Adequacy of the safety database ........................................................................... 42
8.3. Adequacy of Applicant’s Clinical Safety Assessments.................................................... 42
8.3.1. Issues Regarding Data Integrity and Submission Quality ....................................... 42
8.3.2. Categorization of Adverse Events ........................................................................... 42
8.3.3. Routine Clinical Tests .............................................................................................. 43

Clinical Review
NDA 208398 – 505(b)(2)
8.4. Safety Results ................................................................................................................. 43

8.4.1. Deaths ..................................................................................................................... 43
8.4.2. Serious Adverse Events ........................................................................................... 43
8.4.3. Dropouts and/or Discontinuations Due to Adverse Effects ................................... 43
8.4.4. Significant Adverse Events ...................................................................................... 43
8.4.5. Treatment Emergent Adverse Events and Adverse Reactions ............................... 44
8.4.6. Laboratory Findings ................................................................................................ 47
8.4.7. Vital Signs ................................................................................................................ 47
8.4.8. Electrocardiograms (ECGs)...................................................................................... 47
8.4.9. QT ............................................................................................................................ 47
8.4.10. Immunogenicity ............................................................................................... 47
8.5. Analysis of Submission-Specific Safety Issues ................................................................ 47
8.5.1. Feeding Status......................................................................................................... 47
8.5.2. Age .......................................................................................................................... 49
8.6. Safety Analyses by Demographic Subgroups ................................................................. 54
8.7. Specific Safety Studies/Clinical Trials – Internal Clinical Studies ................................... 54
8.8. Additional Safety Explorations ....................................................................................... 56
8.8.1. Human Carcinogenicity or Tumor Development .................................................... 56
8.8.2. Human Reproduction and Pregnancy ..................................................................... 56
8.8.3. Pediatrics and Assessment of Effects on Growth ................................................... 58
8.8.4. Overdose, Drug Abuse Potential, Withdrawal, and Rebound ................................ 58
8.9. Safety in the Postmarket Setting.................................................................................... 59
8.9.1. Safety Concerns Identified Through Postmarket Experience ................................. 59
8.10. Expectations on Safety in the Postmarket Setting ..................................................... 61
8.11. Additional Safety Issues From Other Disciplines ........................................................ 61
8.12. Integrated Assessment of Safety ................................................................................ 62
9 Advisory Committee Meeting and Other External Consultations ......................................... 62
10 Labeling Recommendations .................................................................................................. 62

10.1. Prescribing Information .............................................................................................. 62
10.2. Patient Labeling .......................................................................................................... 65

Clinical Review
NDA 208398 – 505(b)(2)
10.3. Nonprescription Labeling ........................................................................................... 65
11 Risk Evaluation and Mitigation Strategies (REMS) ................................................................ 65
12 Postmarketing Requirements and Commitments ................................................................. 65
13 Appendices ............................................................................................................................ 66
13.1. References .................................................................................................................. 66
13.2. Financial Disclosure .................................................................................................... 70
13.3. Current Treatment Options for Soil Transmitted Helminth Infections ...................... 71
13.4. Overall Study Design for GAI3003 .............................................................................. 73
13.5. Time and Events Schedule for GAI3003 ..................................................................... 74
13.6. Demographic Characteristics of Subjects in Studies GAI3002 and GAI3003 ............. 75
13.7. Disposition of Subjects in Studies GAI3002 and GAI3003 .......................................... 76
13.8. Treatment Emergent Adverse Events by System Organ Class and Dictionary-derived
Terms for Study GAI1002 - Safety Population .......................................................................... 77
13.9. Treatment Emergent Adverse Events by Food State for Study GAI3003 Double Blind
Phase - Safety Population ......................................................................................................... 78
13.10. Treatment Emergent Adverse Events by Food State for Study GAI3003 Open Label
Phase - Safety Population ......................................................................................................... 79
13.11. Treatment Emergent Adverse Events by Age for Study GAI3002 - Safety Population
80
13.12. Treatment Emergent Adverse Events by Age for Study GAI1003 Double-Blind Phase -
Safety Population ...................................................................................................................... 81
13.13. Treatment Emergent Adverse Events by Age for Study GAI1003 Open Label Phase -
Safety Population ...................................................................................................................... 82
13.14. Systemic Exposure (AUC) to Mebendazole and its Metabolites – Clinical Studies and
Literature .................................................................................................................................. 83
13.15. Pregnancy Outcomes with Mebendazole Exposure................................................... 84
13.16. Interval and Cumulative Postmarketing Exposure ..................................................... 87

Clinical Review
NDA 208398 – 505(b)(2)
Table of Tables
Table 1: Summary of Key Regulatory Interactions ....................................................................... 19

Table 2 Mean (SD) Mebendazole Pharmacokinetic Parameters for Pediatric Subjects and
Healthy Adult Subjects. ................................................................................................................. 23
Table 3 Mean Capillary Whole Blood Mebendazole Pharmacokinetic Parameters by Age Group
and Comparison with the Plasma Pharmacokinetic Parameter Estimates in Adults ................... 23
Table 4 Clinical Studies for Mebendazole Chewable 500 mg Tablet ............................................ 25
Table 5 Cure rates at the end of the double-blind period (Day 19) – ITT Population .................. 30
Table 6 Egg Reduction Rates for A. lumbricoides at the end of the double-blind period (Day 19) –
ITT Population ............................................................................................................................... 31
Table 7 Egg Reduction Rates for T. trichiura at the end of the double-blind period (Day 19) – ITT
Population ..................................................................................................................................... 31
Table 8 Literature Summary of Efficacy of 500-mg Single-Dose Mebendazole Against Ascaris
lumbricoides – All Studies, Including Placebo-Controlled Trials ................................................... 34
Table 9 Literature Summary of Efficacy of 500-mg Single-Dose Mebendazole Against Trichuris
trichiura - All Studies, Including Placebo-Controlled Trials .......................................................... 34
Table 10 Literature Summary of Efficacy of 500-mg Single-Dose Mebendazole Against
(b) (4)
.............................................................................................................. 35
(b) (4)
........................................................................................................................................... 36
Table 12 Analysis of Cure Rate by STH Infection at Baseline (Single- and Double-Worm
Infections) ..................................................................................................................................... 39
Table 13: Clinical Studies - Summary of Exposure ........................................................................ 41
Table 14 Treatment-Emergent Adverse Events by Body System (GAI3002 and GAI3003 [Double-
Blind Phase]) - Safety Population.................................................................................................. 45
Table 15 Treatment-Emergent Adverse Events by Body System Open-Label Follow-Up Phase
(GAI3003) - Safety Population. ..................................................................................................... 46
Table 16 Frequency of Treatment Emergent Adverse Events by Age Group for Study GAI3003
(Overall) - Safety Population ......................................................................................................... 50
Table 17 Number of internal clinical studies reporting an adverse event ................................... 55
Table 18 Important Identified Risks, Important Potential Risks, and Missing Information ......... 60
Table 19 Summary of Labeling Recommendations ...................................................................... 62
Table 20 Current Treatment Options for Soil Transmitted Helminth Infections.......................... 71
Table 21 Time and Events Schedule for GAI3003 ......................................................................... 74
Table 22 Demographic Characteristics of Subjects in Studies GAI3002 and GAI3003 – Safety
Population. .................................................................................................................................... 75
Table 23 Disposition of Subjects in Studies GAI3002 and GAI3003 (Double-Blind Phase) – All
Subjects. ........................................................................................................................................ 76

Clinical Review
NDA 208398 – 505(b)(2)
Table 24 Treatment Emergent Adverse Events by System Organ Class and Dictionary-derived
Terms for Study GAI1002 - Safety Population .............................................................................. 77
Table 25 Treatment Emergent Adverse Events by Food State for Study GAI1003 Double Blind
Phase - Safety Population. ............................................................................................................ 78
Table 26 Treatment Emergent Adverse Events by Food State for Study GAI1003 Open Label
Phase - Safety Population. ............................................................................................................ 79
Table 27 Treatment Emergent Adverse Events Occurring at Greater Than or Equal to 1% by
System Organ Class and Dictionary Derived Term by Age Group for GAI3002 - Safety Population.
....................................................................................................................................................... 80
Table 28 Treatment Emergent Adverse Events by Age for Study GAI3003 Double Blind Phase -
Safety Population. ......................................................................................................................... 81
Table 29 Treatment Emergent Adverse Events by Age for Study GAI3003 Open Label Phase -
Safety Population. ......................................................................................................................... 82
Table 30 Systemic Exposure (AUC) to Mebendazole and its Metabolites After Single or Repeated
Oral Doses ..................................................................................................................................... 83
Table 31 Pregnancy Outcomes and Mebendazole Exposure ....................................................... 84
Table 32 Exposure to mebendazole and mebendazole/quinfamide (01 May 2015 to 30 April
2016) ............................................................................................................................................. 87
Table 33 Exposure to mebendazole and mebendazole/quinfamide (1988 to 30 April 2016) ..... 87

Clinical Review
NDA 208398 – 505(b)(2)
Table of Figures
Figure 1 Overall Study Design for GAI3003................................................................................... 73

Clinical Review
NDA 208398 – 505(b)(2)
Glossary
AC advisory committee
AE adverse event
BLA biologics license application
BPCA Best Pharmaceuticals for Children Act
BRF Benefit Risk Framework
CBER Center for Biologics Evaluation and Research
CDER Center for Drug Evaluation and Research
CDRH Center for Devices and Radiological Health
CDTL Cross-Discipline Team Leader
CFR Code of Federal Regulations
CMC chemistry, manufacturing, and controls
COSTART Coding Symbols for Thesaurus of Adverse Reaction Terms
CRF case report form
CRO contract research organization
CRT clinical review template
CSR clinical study report
CSS Controlled Substance Staff
DMC data monitoring committee
DPMH Division of Pediatrics and Maternal Health
ECG electrocardiogram
eCTD electronic common technical document
ETASU elements to assure safe use
FDA Food and Drug Administration
FDAAA Food and Drug Administration Amendments Act of 2007
FDASIA Food and Drug Administration Safety and Innovation Act
GCP good clinical practice
GRMP good review management practice
ICH International Conference on Harmonization
IND Investigational New Drug
ISE integrated summary of effectiveness
ISS integrated summary of safety
ITT intent to treat
MedDRA Medical Dictionary for Regulatory Activities
mITT modified intent to treat
NCI-CTCAE National Cancer Institute-Common Terminology Criteria for Adverse Event
NDA new drug application

Clinical Review
NDA 208398 – 505(b)(2)
NME new molecular entity

OCS Office of Computational Science
OPQ Office of Pharmaceutical Quality
OSE Office of Surveillance and Epidemiology
OSI Office of Scientific Investigation
PBRER Periodic Benefit-Risk Evaluation Report
PD pharmacodynamics
PI prescribing information
PK pharmacokinetics
PMC postmarketing commitment
PMR postmarketing requirement
PP per protocol
PPI patient package insert
PREA Pediatric Research Equity Act
PRO patient reported outcome
PSUR Periodic Safety Update report
REMS risk evaluation and mitigation strategy
SAE serious adverse event
SAP statistical analysis plan
SGE special government employee
SOC standard of care
STH soil-transmitted helminth
TEAE treatment emergent adverse event
WHO World Health Organization

Clinical Review
NDA 208398 – 505(b)(2)
2 Therapeutic Context
2.1. Analysis of Condition
Soil transmitted helminth (STH) infections are considered a neglected tropical disease. STH
infections are caused by four main species of parasitic worms: roundworm (Ascaris
lumbricoides), whipworm (Trichuris trichiura) and hookworms (Necator
americanus and Ancylostoma duodenale).
The World Health Organization (WHO) estimates that more than 1.5 billion people, or 24% of
the world’s population, have soil-transmitted helminth (STH) infections.1 Furthermore, there
are over 270 million preschool children and over 600 million school-age children living in areas
of intense transmission, and are in need of treatment and prevention interventions.1
Morbidity from STH infections is related to worm burden and can include nutritional
impairment (i.e., intestinal bleeding, impaired iron status, anemia, nutrient malabsorption,
competition for micronutrients, impaired growth, loss of appetite, reduction of food intake,
diarrhea, dysentery), cognitive impairment, intestinal obstruction and rectal prolapse.2, 3
WHO recommends control of STH infections to decrease morbidity by periodic treatment of at-
risk populations living in endemic areas.9 At-risk individuals include preschool children, school-
age children, women of childbearing age (including pregnant women in the second and third
trimesters and breastfeeding women) as well as adults in certain high-risk occupations, such as
tea pickers and miners. Periodic treatment decreases worm burden, which can decrease
morbidity.
WHO recommends single dose mebendazole (500 mg) or albendazole (400 mg) for treatment of
STH infections.
2.2. Analysis of Current Treatment Options
There are four drugs on the WHO Model List of Essential Medicines for the treatment and
control of STH infections: mebendazole, albendazole, levamisole, and pyrantel pamoate (Table
20).5, 6 In addition, ivermectin can be used for the treatment of STH.5, 7 Only the mebendazole
100 mg chewable tablet form is FDA approved for multi-dose treatment of STH.7, 8 Albendazole,
pyrantel pamoate and ivermectin are FDA-approved for other indications. Levamisole is FDA
approved for veterinary use.
Mebendazole and albendazole, both benzimidazole antihelminthics, are frequently used for

Clinical Review
NDA 208398 – 505(b)(2)
WHO single-dose mass drug administration STH public health programs.2, 9 The dosing regimen
for the currently approved mebendazole 100 mg chewable tablet (twice daily for 3 days) is not
practical for STH mass drug administration programs. In addition, the 100 mg chewable tablet
may pose dosing challenges in children less than 3 years of age who may not be able to chew
the tablet.
There is a mebendazole 500 mg solid oral tablet formulation available outside the U.S. which
can be crushed and administered with a small amount of potable water, if available, for
children less than 5 years old. This is not a preferred method of administration for several
reasons: 1.) additional work required for crushing the tablet, 2.) unpleasant taste of the
medication, 3.) possible choking hazard if the medication is not completely crushed, and 4.)
chance of insufficient dosing if part of the medication is lost. WHO recommends that only
chewable deworming tablets should be given to children under 5 years old, and that chewable
tablets be crushed and mixed with water in children under 3 years old. The WHO recommends
a 500-mg chewable dose for all ages ш1 year, with no adjustment in dosage needed based on
age, weight or surface area.4
3 Regulatory Background
3.1.U.S. Regulatory Actions and Marketing History
The approved reference product is VERMOX (mebendazole) 100 mg chewable tablets (NDA
017481, approved 28 June 1974). Marketing for VERMOX (mebendazole) 100 mg chewable
tablets was discontinued in 2006 due to commercial reasons; however safety reporting
continues.
3.2. Summary of Presubmission/Submission Regulatory Activity
A summary of key regulatory interactions is summarized in Table 1. Please refer to the Clinical
Review for the pre-NDA meeting filed under IND 115959 SD25 for additional details.

Clinical Review
NDA 208398 – 505(b)(2)
Table 1: Summary of Key Regulatory Interactions
Source: NDA 208398, Module 1.2, Reviewer’s Guide, Regulatory History.
3.3. Foreign Regulatory Actions and Marketing History
Mebendazole is licensed in 123 countries around the world. The registered formulations of
mebendazole are 100-mg, 200-mg, and 500-mg oral tablets, 500-mg chewable tablets, and oral
suspensions of 20 mg/mL, 40 mg/mL, 50 mg/mL, 60 mg/mL, and 100 mg/5 mL. The 500-mg
solid oral tablet of VERMOX (mebendazole) was first registered in Belgium in March 1971 and is
used in approximately 60 countries for the mass treatment of single or mixed gastrointestinal
infections by E. vermicularis, T. trichiura, A. lumbricoides, A. duodenale, and N. americanus.
Both the 100-mg and 500-mg chewable tablets are listed in the World Health Organization
(WHO) Model List of Essential Medicines for Children for the treatment of STH infections.
Currently, the Applicant is donating the commercial 500-mg VERMOX solid oral tablets to the
WHO for distribution to countries with moderate-to-high prevalence of STH infections for
single-dose preventive chemotherapy programs in school-age children.

Clinical Review
NDA 208398 – 505(b)(2)
4 Significant Issues from Other Review Disciplines Pertinent to Clinical

Conclusions on Efficacy and Safety
4.1. Office of Scientific Investigations (OSI)
The Division of Good Clinical Practices within the Office of Scientific Investigations was
consulted on 23 May 2016. Only foreign data are used to support the application and only one
Phase 3 study (GAI3003) was conducted. Study GAI3003 was conducted at 3 clinical sites, 2 in
Ethiopia (Gondar and Jimma) and 1 in Rwanda (Kigali). Because the majority (255/ 295) of
subjects was enrolled at the Ethiopian sites, DAIP requested that these sites be inspected. The
inspection summary goal date was 15 September 2016; however there were challenges due to
the local security situation, particularly at the Gondar, Ethiopia site. The inspection was
completed at the Jimma, Ethiopia site on 21 September 2016 and the preliminary field
classification was No Action Indicated (NAI). Please see the OSI review by John Lee, M.D. for
additional information. Please refer to Section 6.2.1 for details regarding the Applicant’s pre-
FDA site inspection findings.
4.2. Product Quality
Please refer to the relevant Product Quality Reviews for this NDA.
Note that two different mebendazole 500 mg formulations were used during the clinical
development program (Table 4). The Applicant initially developed a mebendazole 500 mg
chewable tablet. Subsequently, the Applicant developed a rapidly disintegrating mebendazole
500mg chewable tablet which turns into a soft semi-solid mass with the addition of 2 to 3 mL of
water. This new rapidly disintegrating chewable tablet was used in the Phase 3 study and is
referred to as the new mebendazole 500 mg chewable tablet throughout the review.
According to FDA June 2016 Draft Guidance for Industry entitled, ‘Quality Attribute
Considerations for Chewable Tablets’, the nomenclature, “[DRUG] Chewable Tablets” will be
used for tablets that MUST be chewed and for which there is no alternative route of
administration.10 In addition, the Guidance states that ‘The labels and labeling for these
products will also include a labeling statement indicating that the tablets MUST be chewed’.
Application of this Guidance to the proposed product was a conundrum for the review team.
The product is a chewable tablet too large to be swallowed whole; however in patients who
have difficulty chewing, 2 to 3 mL of water turns the tablet into a soft mass with semi-solid
consistency (see video submitted to IND 115959, July 2013). Multiple discussions were held
with the Office of Product Quality (OPQ) regarding the appropriate nomenclature and labeling
of the mebendazole 500 mg chewable tablet. This involved OPQ representatives from the

Clinical Review
NDA 208398 – 505(b)(2)
Office of New Drug Products (including Dorota Matecka, PhD and George Lunn, PhD) and Office
of Policy for Pharmaceutical Quality (including Yana Mille, RPh and Richard Lostritto, PhD).
Ultimately, the team agreed upon the name of ‘VERMOXTM CHEWABLE (mebendazole chewable
tablet)’. In Section 2 Dosage and Administration of the label, directions on how to turn the
tablet into a semi-solid mass are provided without a separate heading of ‘Alternate Methods of
Administration’.
4.3. Clinical Microbiology
Please refer to the Clinical Microbiology Review by Shukal Bala, PhD. Dr. Bala notes that, in
rodents and dogs experimentally infected with different helminth species, as well as naturally
infected dogs, multiple doses of mebendazole were effective in reducing parasite burden. In
vitro and in vivo studies suggest a potential for development of STH resistance to mebendazole
(b) (4)
due to a in the parasite ɴ-tubulin gene. However,
an association between mutations in the STH ɴ-tubulin gene and clinical response in human
subjects with STH has not been evaluated. Furthermore, the Phase 3 study (GAI3003) and
published studies suggest that a single 500 mg dose of mebendazole is effective in curing and
reducing egg count in patients infected with A. lumbricoides, T. trichiura, A. duodenale, and N.
americanus. Dr. Bala also notes that A. lumbricoides appears to be more sensitive compared to
T. trichiura and hookworms (A. duodenale and N. americanus). The major effect is on
decreasing the egg count. Dr. Bala concludes that treatment with a single dose of mebendazole
should be effective in decreasing the intensity and reducing transmission of STH infections.
Please refer to Dr. Bala’s review for details.
Note that on 6 September 2016 the Applicant notified the Division of a protocol deviation in the
recording of consensus Kato-Katz egg count values from the Quality Control readings to the
Case Report Forms. Several follow-up information requests were sent to the Applicant for
clarification. Ultimately, it was determined that the protocol deviations affected the final
clinical outcome in 3 subjects and did not substantially impact efficacy conclusions.
4.4. Nonclinical Pharmacology/Toxicology
Please refer to the Pharmacology Toxicology Review by Amy Nostrandt, DVM, PhD.
In carcinogenicity tests of mebendazole in mice and rats, no carcinogenic effects were seen at
doses as high as 40 mg/kg (0.4 to 0.8-fold the MRHD, based on mg/m2) given daily over two
years. No mutagenic activity was observed with mebendazole in a bacterial reverse gene
mutation test. Mebendazole was mutagenic in the absence of S-9 when tested using a
continuous (24 hour) treatment incubation period in the mouse lymphoma thymidine kinase

Clinical Review
NDA 208398 – 505(b)(2)
assay. Mebendazole was aneugenic in vitro in mammalian somatic cells. In the in vivo mouse
micronucleus assay, orally administered mebendazole induced an increased frequency of
micronucleated polychromatic erythrocytes with evidence suggestive of aneugeniciy. Doses up
to 40 mg/kg in rats (0.8-fold the MRHD, based on mg/m2), given to males for 60 days and to
females for 14 days prior to gestation, had no effect upon fetuses and offspring.
4.5. Clinical Pharmacology
Please refer to the Clinical Pharmacology Review by Abhay Joshi, PhD.
4.5.1. Mechanism of Action
Mebendazole acts locally in the intestinal lumen of humans to interfere with cellular tubulin
formation within the intestines of STH resulting in disrupted glucose uptake and digestive
functions which ultimately lead to autolysis and parasite death.
4.5.2. Pharmacodynamics
Similar to other formulations, the new mebendazole 500 mg chewable tablet is poorly
absorbed after oral administration.
4.5.3. Pharmacokinetics
A summary of mean mebendazole pharmacokinetic (PK) parameters in Studies GAI3003 and

GAI1002 is shown in Table 2. In both studies, subjects received the new mebendazole 500 mg
chewable tablet. Please refer to the Analysis of Submission Specific Safety Issues in Sections
8.5.1 Feeding Status and 8.5.2 Age for detailed discussion regarding PK and safety from a
clinical perspective.

Clinical Review
NDA 208398 – 505(b)(2)
4.5.4 Review Issues Identified by Clinical Pharmacology
The Clinical Pharmacology reviewer, Abhay Joshi, PhD identified three main review issues with
the application. Please refer to Dr. Joshi’s review for details.
1. Higher systemic exposure to mebendazole in young children (age 1 to less than 3

years): The mean mebendazole systemic exposure from a single dose of 500 mg
mebendazole chewable tablet was approximately 4-fold higher in the youngest
pediatric patients (1 to < 3 years) than the older pediatric patients (3 to < 7 years
and 7 to 16 years) and adults. The higher exposure was partially attributed to the
fixed (“non-weight normalized”) dosing strategy of one 500 mg chewable tablet
as a one-time dose. However, the observed higher exposure in pediatrics (>1
years) was deemed clinically insignificant based on the safety data from the same
study. Thus, the proposed single one-time 500 mg dose of Vermox Chewable in
pediatric patients is acceptable from a Clinical Pharmacology perspective.
2. Food effect: In healthy volunteers, administration of the newer to-be-marketed

mebendazole chewable tablet formulation with a high fat breakfast resulted in
approximately 3- to 4-fold higher systemic exposure compared to when administered
under fasted conditions. However, there was no apparent association between higher
systemic exposure and safety findings, based on review of safety data from the
same study. Thus, Vermox Chewable tablets will be recommended to be given
without regard to meals/food.
3. Capillary sampling method: The Applicant’s proposal to use whole blood

mebendazole concentrations from fingerstick capillary samples as a surrogate for
venous PK plasma sampling was not acceptable because of the observed sporadic higher
concentrations in some capillary samples, in both pediatrics and adults. For the majority
of inconsistences, mebendazole concentrations in capillary fingerstick samples were
higher than concentrations in respective venous plasma samples; therefore, it can be
approximated that the mebendazole plasma levels will be equal or lower than the levels
that are detected in the fingerstick samples. Therefore, the Reviewer agrees with the
Applicant’s proposed approach of using mebendazole concentrations in whole blood
capillary fingerstick samples as “worst case” or “maximum” estimates for the systemic
PK exposure to mebendazole.
4.6. Devices and Companion Diagnostic Issues
This section is not applicable.

Clinical Review
NDA 208398 – 505(b)(2)
4.7. Consumer Study Reviews
5 Sources of Clinical Data and Review Strategy
5.1.Table of Clinical Studies
The Applicant submits information from 4 clinical studies (Table 4), internal study reports and
the literature.
Table 4 Clinical Studies for Mebendazole Chewable 500 mg Tablet
Source: NDA 208398, Module 2.5, Clinical Overview, Table 1.
5.2.Review Strategy
The Applicant submits data from clinical studies, internal study reports and the literature to
support the use of the new mebendazole 500 mg chewable tablet for single dose treatment of

Clinical Review
NDA 208398 – 505(b)(2)
single- or mixed- species infections. This clinical reviewer considered all sources of data in
review of this application. Efficacy analyses were conducted by the Statistical Reviewer, Janelle
Charles, PhD. Supportive analyses were conducted by the Clinical Microbiology Reviewer,
Shukal Bala, PhD. All safety analyses were conducted by this Clinical Reviewer. Please refer to
Section 8.1 for the Safety Review Approach.
6 Review of Relevant Individual Trials Used to Support Efficacy
6.1.MEBENDAZOLGAI3002
6.1.1. Study Design
MEBENDAZOLGAI3002 was an open-label, single-dose study to assess the safety of the

‘previous’ 500 mg mebendazole chewable tablet in children 2 to 10 years of age, inclusive.
MEBENDAZOLGAI3002 is referred to as GAI3002 throughout the review. GAI3002 was not used
to support efficacy; however is briefly described here for reference purposes.
GAI3002 was conducted at one site, Pemba Island in Zanzibar, Tanzania.
According to the Applicant, the “study was conducted in accordance with the ethical principles
that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical
Practices and applicable regulatory requirements”.
Study visits included the following:

1. Day 1: Screening visit. Eligible children entered into the study and administered a
single mebendazole 500-mg chewable tablet. The children remained at the study center
and AEs were recorded at approximately 30 minutes postdose.
2. Day 3 (±1 day): Subjects returned to the study center for safety assessments,
including AEs, changes in vital sign measurements, and physical examinations.
6.1.2. Study Results
Please refer to Section 8.
6.2. MEBENDAZOLGAI3003
6.2.1. Study Design
Overview and Objective
MEBENDAZOLGAI3003 is entitled “A Double-Blind, Randomized, Multi-Center, Parallel-Group,

Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg

Clinical Review
NDA 208398 – 505(b)(2)
Chewable Tablet of Mebendazole in the Treatment of Soil-Transmitted Helminth Infestations

(Ascaris lumbricoides and Trichuris trichiura) in Pediatric Subjects”. MEBENDAZOLGAI3003 will
be referred to as GAI3003 throughout the review.
Objectives:
1. Primary: Compare the efficacy and safety of a single dose of a new 500-mg chewable
mebendazole tablet with placebo in the treatment of Ascaris lumbricoides and Trichuris
trichiura infestations in pediatric subjects.
2. Secondary: Assess systemic exposure to mebendazole following oral dosing of a 500-

mg chewable tablet in pediatric subjects.
3. Exploratory: Compare efficacy and safety of the 500-mg chewable mebendazole

(b) (4)
tablet to placebo in treatment of in pediatric subjects.
Hypotheses:
Null hypothesis 1: In children infected with A. lumbricoides, cure rate (CR) is comparable
following treatment with a single dose of a 500 mg chewable mebendazole tablet
compared with placebo. Cure was defined as average posttreatment zero egg count.
Null hypothesis 2: In children infected with T. trichiura, CR is comparable following

treatment with a single dose of a 500-mg chewable mebendazole tablet compared with
placebo.
Trial Design
GAI3003 was a Phase 3, randomized, double-blind, placebo-controlled, multicenter study

conducted to assess the efficacy and safety of a single dose of a 500-mg chewable mebendazole
tablet for the treatment of A. lumbricoides and T. trichiura infections in children between the
ages of 1 and 16 years.
GAI3003 was conducted at three sites, 2 in Ethiopia (Gondar and Jimma) and 1 in Rwanda
(Kigali). In order to ensure the safety of study subjects, an Independent Data Monitoring
Committee (IDMC) was established to review unblinded study data. A pharmacokinetic (PK)
substudy was also conducted. According to the Applicant, the “study was conducted in
accordance with the ethical principles that have their origin in the Declaration of Helsinki and
that are consistent with Good Clinical Practices and applicable regulatory requirements”.
The overall study design for GAI3003 is summarized in Figure 1 and Table 21. The study
included 5 site visits:
1. Day -3 to -1: Screening
2. Day 1: Baseline and randomization, and initiation of double-blind treatment

Clinical Review
NDA 208398 – 505(b)(2)
3. Day 19±2: End of double-blind phase; collection of stool sample for efficacy
evaluation in the double-blind phase, mebendazole dosing to all subjects, starting in
the open label phase, and collection of the first blood samples for PK analysis (for PK
sub-study subject)
4. Day 20±2: Collection of the last blood samples for PK analysis
5. Day 26±3: Complete the open label follow-up phase
Key Inclusion Criteria:

1. Male or female subjects of age 1 to 16 years, inclusive, living in a high STH-prevalence
area.
2. Female subjects ш9 years old who had negative urine pregnancy test at screening or
at the time of randomization.
3. Subjects, who were otherwise healthy, based on medical history, physical
examination, vital signs, hemoglobin, and concomitant medications.
5. Subjects were available to return to the study site for all visits, including follow-up.
6. Parent(s)/guardians of subjects (or legally-accepted representatives) provided signed
informed consent document and were willing to have the child participate in the study.
7. Children ш6 years of age were asked to assent to their participation using age-
appropriate language to agree to participate
Study Drugs
The ‘new’ mebendazole chewable 500 mg chewable tablet and a matching placebo
tablet were used in the study (Table 4). For children 3 to 16 years of age, the study drug
was administered as a tablet which was chewed and swallowed without water. For
children 1 to <3 years of age, the tablet was placed on a teaspoon and approximately
half spoonful (2 to 3 mL) of drinking water was added using a dosing syringe onto the
tablet. The resulting soft mass with a semi-solid consistency was administered.
Study Endpoints
The two primary efficacy endpoints were cure rates (CR) for A. lumbricoides and T. trichiura
infections at the end of the double-blind period for subjects with positive corresponding egg
counts at baseline.
Secondary efficacy endpoints were egg count reductions (ER) for A. lumbricoides and T.
trichiura infections at the end of the double-blind period.
The baseline value for efficacy analyses was the average positive egg count for the respective
STH from the screening visit.

Clinical Review
NDA 208398 – 505(b)(2)
(b) (4)
Protocol Amendments
There were four non-substantive protocol amendments. Please refer to the clinical study
report for details.
Data Quality and Integrity: Sponsor's Assurance
The Applicant reports appropriate steps taken to ensure the accuracy and reliability of the data.
Reviewer Comment: On 06 September 2016, the Division received a communication from the
Applicant regarding their pre-FDA site inspection results conducted on August 1 and 2, 2016.
The Applicant identified a deviation from the Quality Control (QC) procedure at the study sites
and two protocol deviations in the PK sub-study.
The protocol deviation for QC involved failure of accurate transcription of results to case report
forms when a new consensus value was documented. This ‘QC transcription deviation’ was
noted in 11 QC check samples from 9 subjects and impacted the outcome of cure in 3 subjects
(251001043, 251002044 and 251002101). Re-analysis of efficacy using the updated results
based on QC did not significantly change the results. Please refer to the relevant Applicant
submissions submitted to the NDA for details.
In the PK sub-study, a patient who spit out the dose or vomits within 4 h after treatment was
considered to be no longer PK evaluable. However, there were two children included in their
analysis who should not have been. There was one child (251001272) who spit out part of the
mebendazole 500 mg chewable tablet administered as a semi-solid mass on a spoon at Visit 3.
The child was re-dosed in a similar manner and spit out part of the second dose. This child was
considered to have received at least 50 % of the dose and therefore described as “treatment
compliant”. There was a second child (251002233) in the PK substudy who spit out part of the
mebendazole 500 mg chewable tablet administered as a semi-solid mass on a spoon at Visit 3.
The child was considered to have received at least 50 % of the dose and therefore described as
“treatment compliant”. Excluding these two subjects (251001272 and 251002233) from the PK
analysis decreased the mean values for mebendazole Cmax and AUClast for the 1-3 year age class
(Table 3). Please refer to the Clinical Pharmacology Review for additional details.
Both the ‘QC transcription deviation’ and ‘PK sub-study protocol deviations’ were reviewed in
detail at several internal Division meetings (September 6, 13, 27, and 30, 2016) . In addition the
Division discussed these findings with the Applicant via teleconference on 13 September 2016.

Clinical Review
NDA 208398 – 505(b)(2)
Table 6 Egg Reduction Rates for A. lumbricoides at the end of the double-blind period (Day
19) – ITT Population
Source: NDA 208398, Statistical Review, Table 5, Janelle Charles, PhD.
Table 7 Egg Reduction Rates for T. trichiura at the end of the double-blind period (Day 19) –
ITT Population
Source: NDA 208398, Statistical Review, Table 6, Janelle Charles, PhD.

Clinical Review
NDA 208398 – 505(b)(2)
Reviewer Comment: Treatment with the new mebendazole 500 mg chewable tablet results in
cure rates and egg reduction rates for T. trichiura and A. lumbricoides which are superior to
placebo. Cure rates and egg reduction rates for T. trichiura are lower than A. lumbricoides.
These results are consistent with the published literature. For example, one large published
study (n=5830) evaluating efficacy of mebendazole in 6 countries on 3 continents confirmed
findings from previous studies that mebendazole reduces fecal egg counts; however it is less
(b) (4) 11-13
efficacious for T. trichiura compared to A. lumbricoides . T. trichiura
infections frequently require 3 days of treatment to achieve cure, rather than single-dose
treatment.6, 13
Because the environment where target populations reside may not change, the goal of public
health mass drug administration programs for STH infections is to decrease worm burden,
rather than eliminate infection, in order to reduce morbidity and minimize severe complications
caused by STH in at-risk populations.2, 9
Please refer to the relevant sub-section of Section 8.4 Safety Results for a description of patient
disposition and demographic characteristics.
Please refer to the Statistical Review for details regarding the efficacy analysis.
(b) (4)
In the Applicant’s proposed label,
This reviewer
suggests displaying data using geometric means in the proposed label.
Efficacy Results – Exploratory Endpoint
Thirteen randomized subjects had hookworm infection in addition to Ascaris lumbricoides

(b) (4)
and/or Trichuris trichiura infections.
Reviewer Comment: The numbers are too small to make efficacy conclusions for the new
mebendazole 500 mg chewable tablet and cure of hookworm infection solely from Study
GAI3003. Please see Section 7.2.3 for additional details.

Clinical Review
NDA 208398 – 505(b)(2)
7 Integrated Review of Effectiveness
7.1. Assessment of Efficacy Across Trials
7.1.1. Primary Endpoints
Please refer to Section 7.2.1.
7.1.2. Secondary and Other Endpoints
Please refer to Section 7.2.1.
7.1.3. Subpopulations
Subpopulation analyses by age and sex evaluated cure rates for A. lumbricoides and T. trichiura
after treatment with the new mebendazole 500 mg chewable tablet. Cure rates were similar
between females and males, as well as across age groups.
Reviewer Comment: Please refer to the Statistical Review for details.
7.1.4. Dose and Dose-Response
The Applicant develops a new mebendazole 500 mg chewable tablet intended for single-dose
mass drug administration STH public health programs. The new formulation complies with
WHO recommendations that only chewable deworming tablets should be given to children
under 5 years old, and that chewable tablets be mixed with water in children under 3 years
old.14 In the United States, a multi-dose mebendazole regimen (100 mg twice daily for 3 days)
is approved.8
7.1.5. Onset, Duration, and Durability of Efficacy Effects
The antihelminthic effect is directly related to the presence of mebendazole in the

gastrointestinal tract. Using the same benzimidazole drugs for STH infections can theoretically
place selection on the ɴ-tubulin gene, leading to resistance.15, 16 Resistance has not yet been
described in STH mass drug administration programs.
7.2. Additional Efficacy Considerations
7.2.1. Considerations on Benefit in the Postmarket Setting - A. lumbricoides, T.

trichiura Infections
(b) (4)
The Applicant conducted a literature review summarizing efficacy data for a single-dose
mebendazole 500 mg regimen (any formulation). Cure rates [CRs] and egg reduction rates

Clinical Review
NDA 208398 – 505(b)(2)
[ERs]) were abstracted for each study. Weighted means, where the treatment group results
were weighted proportionally to the number of subjects treated, were used to calculate overall
cure rates and egg reduction rates.
(b) (4)
The Applicant’s summary of efficacy for A. lumbricoides, T. trichiura, are
summarized in Table 8, Table 9, and Table 10.
Table 8 Literature Summary of Efficacy of 500-mg Single-Dose Mebendazole Against Ascaris

lumbricoides – All Studies, Including Placebo-Controlled Trials
Table 9 Literature Summary of Efficacy of 500-mg Single-Dose Mebendazole Against Trichuris

trichiura - All Studies, Including Placebo-Controlled Trials

Clinical Review
NDA 208398 – 505(b)(2)
(b) (4)
Reviewer Comment: Overall cure rates and egg reduction rates from the literature indicate that
a single 500 mg mebendazole dose is superior to placebo for A. lumbricoides and T. trichiura.
(b) (4)
This is consistent with findings in Study GAI3003.
(b) (4)
The Statistics Reviewer, Janelle Charles, PhD, identified 6 placebo-controlled trials from the
Applicant’s literature review, where a total of 571 mebendazole patients and 557 placebo
patients were evaluated for clearance of hookworm eggs at the end of the respective treatment
periods (Table 11).17-22 Treatment follow-up varied from 2 weeks up to 4 weeks and ages of
patients ranged from 2 to 71 years. Reported clinical cure rates ranged from 2.9% to 91.1% for
mebendazole and 0% to 33% for placebo across all studies. Please refer to the Statistics Review
by Janelle Charles, PhD for details.

Clinical Review
NDA 208398 – 505(b)(2)
7.2.2. Considerations on Benefit in the Postmarket Setting - Adults
The Applicant seeks approval of the new mebendazole 500 mg chewable tablet for both
pediatric and adult populations. Although the Phase 3 study, GAI3003, only enrolled children
up to 16 years of age, the Applicant submits a review of the literature for each STH indication,
where studies with adults are included.
Reviewer Comment: This reviewer recommends labeling the new mebendazole chewable tablet
for populations ш 1 year of age (i.e. both pediatric and adult populations).
The current application (NDA 208398) is considered a 505(b)2 submission. The Applicant
submits information cited in published literature regarding efficacy of single-dose mebendazole
500 mg (any formulation) against STH infections (A. lumbricoides, T. trichiura, N. americanus
and A. duodenale) (Section 7.2.1). These publications include studies where both adults and
children were enrolled. Higher efficacy rates were observed with the 500-mg singledose
mebendazole regimens as compared to the placebo arm with respect to both cure rates and egg
reduction rates in each of these studies.
A. lumbricoides: 4 of the 22 studies were placebo controlled studies (age range 2 to 70 years),
with 3 studies reporting results for a placebo-control group (Table 8).17, 18, 23, 24 Two of these
studies17, 24 enrolled adults, with the age of enrollees ranging from 2 to 70 years of age. One of
the studies reported results for a placebo group (age range 2 to 70 years).17 Cure rates for the
mebendazole arm were 93.4% (n=61) and 0% (n=44) in the placebo arm.17 The second study24
was conducted only in adults (age range 18 to 44 years), with cure rates in the mebendazole
arm reported at 72.5% (n=302).
T. trichiura: 5 of the 23 studies included a placebo control group (age range 2 to 70 years), with
4 studies reporting results for a placebo-control group (Table 9).17-19, 23, 24 Two of these studies17,
24
enrolled adults, with the age of enrollees ranging from 2 to 70 years of age. One of the
studies reported results for a placebo group (age range 2 to 70 years).17 Cure rates for the
mebendazole arm were 77.6% (n=67) and 0% (n=38) in the placebo arm.17 The second study24
was conducted only in adults (age range 18 to 44 years), with cure rates in the mebendazole
arm reported at 39.1% (n=391).
(b) (4)

Clinical Review
NDA 208398 – 505(b)(2)
There are additional reasons to support the labeling of the new mebendazole 500 mg chewable
tablet for both adult and pediatric populations. Current labeling for the mebendazole 100 mg
tablet indicates the same dosage schedule for adults and children, with no upper age limit
restrictions.8 Mebendazole (both the new chewable 500 mg tablet and the approved 100 mg
tablet) acts locally within the gastrointestinal tract and has poor systemic absorption. Although
different doses and durations are used for each formulation, both the mebendazole 500 mg and
100 mg tablets use the same dosing regimen for adults and children. Furthermore,
mebendazole would have the same mechanism of action on the soil transmitted helminth,
irrespective of whether the host is an adult or a child. Finally, labelling for both the pediatric
and adult populations will support its intended use as part of WHO single dose mass drug
administration STH public health programs. Restricting the drug to only the pediatric
population may have a significant negative public health impact.
7.2.3. Other Relevant Benefits – Mixed species infections
The Applicant proposes that the new mebendazole 500 mg chewable tablet will be used for
treatment of single and mixed STH infections. However, in the original NDA application, no
data were submitted to support the mixed species aspect of the indication. In response to an
Information Request sent to the Applicant on 09 June 2016, additional information was
provided.
The Applicant provided an analysis of cure rates and egg count reduction rates by single,
double, and triple worm infections at the end of the double blind period for Study GAI3003. Of
the 295 randomized subjects, 49 subjects had single infections with A. lumbricoides (placebo,
n=25; mebendazole, n=24); 124 subjects had single infections with T. trichiura (n=62 in each
group); 109 subjects had double species infections with A. lumbricoides and T. trichiura
(placebo, n=50; mebendazole, n=59). Cure rates and egg count reduction rates for subjects
with single and double infections of A. lumbricoides and T. trichiura in the mebendazole group
are similar. Sample sizes were too small to make any conclusions about mixed-species
infections with hookworm. Note that the study design for GAI3003 excluded patients with only
hookworm infections. Thirteen patients had hookworm infection in addition to Ascaris
(b) (4)
lumbricoides and/or Trichuris trichiura infection.

Clinical Review
NDA 208398 – 505(b)(2)
Table 12 Analysis of Cure Rate by STH Infection at Baseline (Single- and Double-Worm
Infections)
Source: NDA 208398 Statistical Review, Table 11, Janelle Charles, PhD.
The Applicant also reviewed the literature and reported that effectiveness for single- and
mixed-species infections is not described; although the majority of the patients in the studies
have mixed- species infections.
Reviewer Comment: Results from Study GAI3003 are sufficient to support labeling of the new
(b) (4)
mebendazole 500 mg chewable tablet for STH infections. The
relationship of mixed species STH infections and efficacy of any antihelminthic drug is not well
described. Nevertheless, populations receiving STH treatment through mass drug
administration public health programs frequently have mixed-species infections and benefit
from regular antihelminthic treatment.2, 9
Please refer to the Statistics Review by Janelle Charles, PhD for additional details.
7.3. Integrated Assessment of Effectiveness
The new mebendazole 500 mg chewable tablet is effective for the treatment of single- and
mixed- species soil transmitted helminth infections caused by roundworm (Ascaris
(b) (4)
lumbricoides), whipworm (Trichuris trichiura)
populations greater than 1 year of age.
The Applicant conducted one Phase 3, randomized, double-blind, placebo-controlled, study

Clinical Review
NDA 208398 – 505(b)(2)
(GAI3003) at three African sites to assess the efficacy and safety of a single dose of a 500-mg
chewable mebendazole tablet for the treatment of A. lumbricoides and T. trichiura infections in
children between the ages of 1 and 16 years. At the end of the double-blind period (Day 19),
cure rates for subjects in the new mebendazole 500 mg chewable tablet treatment arm were
superior to placebo for A. lumbricoides (mebendazole, 72/86 [83.7%]; placebo, 9/81 [11.1%])
and T. trichiura (mebendazole, 42/124 [33.9%]; placebo, 9/119 [7.6%]). In addition, cure rates
for subjects with single and double infections of A. lumbricoides and T. trichiura in the
mebendazole group were similar and superior to placebo.
The Applicant conducted a literature review summarizing efficacy data for a single-dose
mebendazole 500 mg regimen (any formulation) for the treatment of STH infections. Overall
cure rates abstracted from the literature indicate that a single 500 mg mebendazole dose is
(b) (4)
superior to placebo for A. lumbricoides, T. trichiura, in children and adults.
In both Study GAI3003 and the literature review, cure rates and egg reduction rates were not as
(
high for T. trichiurab in comparison to A. lumbricoides with single dose
)
mebendazole 500 mg treatment (any formulation). However, cure rates and egg reduction
rates were superior to placebo for all STH infections studied.
Single dose benzimidazole treatment (with mebendazole or albendazole) is a key component of

periodic mass drug administration STH public health programs.2, 9 It is well known that
reductions in STH worm burden, even with lower cure rates, can reduce morbidity and
transmission.2, 6, 9, 15 Findings from Study GAI3003 and the literature review support the use of
the new mebendazole 500 mg chewable tablet for treatment of single- and mixed species STH
infections in children and adults.
8 Review of Safety
8.1. Safety Review Approach
The four clinical studies conducted by the Applicant were reviewed for safety issues. In
addition, because mebendazole has been marketed since 1971, reports from internal clinical
studies, postmarketing, and the literature were reviewed. Note that when safety analyses
conducted by the clinical reviewer produced the same results as the Applicant, tables created
by the Applicant are presented in the review.

Clinical Review
NDA 208398 – 505(b)(2)
8.2. Review of the Safety Database
8.2.1. Overall Exposure
Across the four clinical studies, there were 536 children who received one 500 mg dose of
mebendazole and 176 subjects (141 children and 35 adults) who received two 500 mg doses
(Table 13).
Table 13: Clinical Studies - Summary of Exposure
Source: NDA 208398, Module 2.7.4, Summary of Clinical Safety, Table 1.
8.2.2. Relevant characteristics of the safety population
Demographic characteristics of the safety population for Studies GAI3002 and GAI3003 are
briefly summarized in Table 22. In GAI3002, the median age of subjects was 4 years (range 4 –
10 years) with 48.0% females. In GAI3003, the median age of subjects was 8 years (range 1 – 15
years) with 51.5% females. In both GAI3002 and GAI3003, the majority of subjects were Black
or African American (98.7% and 100%, respectively).
Reviewer Comment: The Applicant enrolls children under 3 years of age in their studies which is
a key component to assess safety of the mebendazole chewable 500 mg chewable tablet. The
new rapidly-disintegrating mebendazole 500 mg chewable tablet was specifically developed for
use in the youngest age groups where chewing and swallowing may be difficult. In GAI3002,
62/396 (15.7%) of the subjects were under 3 years of age. In GAI3003, 13/149 (8.7%) subjects in
the mebendazole arm and 14/146 (9.6%) subjects in the placebo arm were under 3 years of age.

Clinical Review
NDA 208398 – 505(b)(2)
8.2.3. Adequacy of the safety database
The Applicant provides an adequate safety database with respect to exposure, demographics
and dose.
8.3. Adequacy of Applicant’s Clinical Safety Assessments
8.3.1. Issues Regarding Data Integrity and Submission Quality
The overall quality of the submission was adequate for the clinical safety review. The Office of
Computational Sciences (OCS) conducted a Data Fitness Assessment which included whether
the data could be loaded into analytic tools for reviewer use, whether certain common analyses
could be performed, availability of appropriate variables, and appropriate use of standard
terminology. No major issues were identified through the Data Fitness Assessment.
8.3.2. Categorization of Adverse Events
The Applicant’s categorization of adverse events was adequate.
TEAEs for GAI3002 were recorded on Day 1 (30 minutes postdose) and 3 days (±1 day) after
study drug administration.
TEAEs for GAI3003 were recorded on Day 1 (up to 3 hours following administration of a 500-mg
chewable mebendazole tablet or matching placebo); Day 19 (up to 3 hours following
administration of an open-label 500-mg chewable mebendazole tablet); and Day 26 (7 days
following administration of the open-label dose).
Reviewer Comment: There are two points regarding datasets and analyses to note for adverse
events.
First, when TEAEs were first reported at the last study visit (i.e. Day 3 for GAI3002 or Day 26 for
GAI3003) or when TEAEs were not completely resolved by the last study visit, there were no end
dates to report in the AEENDTC variable of the dataset. In these cases, the Applicant recorded
the outcome as ‘RECOVERING/RESOLVING’ or ‘NOT RECOVERED/NOT RESOLVED’ in the AEOUT
variable of the ADAE analysis datasets. For both GAI3002 and GAI3003, all TEAEs with end
dates (AEENDTC) had the AEOUT of RECOVERED/RESOLVED.
Second, the Applicant used MedDRA 12.1 for GAI3002 and MedDRA 18.0 for GAI3003 to analyze
TEAEs. This clinical reviewer used MedDRA version 18.0 to analyze TEAEs for both GAI3002 and
GAI3003. AE Term Matching reports did not reveal inconsistencies in Applicant AE reporting for
GAI3002 and GAI3003.

Clinical Review
NDA 208398 – 505(b)(2)
8.3.3. Routine Clinical Tests
No clinical laboratory assessments were conducted for GAI3002 and GAI3003.
8.4. Safety Results
8.4.1. Deaths
In the four clinical studies (GAI1001, GAI1002, GAI3002 and GAI3003), there were no deaths
reported.
8.4.2. Serious Adverse Events
In the four clinical studies (GAI1001, GAI1002, GAI3002 and GAI3003), there were no serious
adverse events reported.
8.4.3. Dropouts and/or Discontinuations Due to Adverse Effects
Disposition of subjects in Studies GAI3002 and GAI3003 are presented in Table 23.
In Study GAI3002, 6 subjects were withdrawn from the study due to non-compliance of study
drug (failure to consume the study medication).
For Study GAI3003, 295 of the 792 subjects screened were enrolled and randomized. Two
hundred seventy-eight subjects (94.2%) completed the double-blind phase and continued into
the open-label phase of the study. Overall, 17 (5.8%) of 295 subjects were withdrawn during
the double-blind phase. Reasons for discontinuation included subject choice (n=12), lost to
follow-up (n=3), protocol violation (n=1; significant wasting), and physician decision (n=1). All
278 subjects who completed the double-blind phase and entered the open label phase
completed the study.
Reviewer Comment: Reasons for subject discontinuation from Study GAI3003 were similar in
both treatment arms.
8.4.4. Significant Adverse Events
In the four clinical studies (GAI1001, GAI1002, GAI3002 and GAI3003), there were no other
significant adverse events reported.

Clinical Review
NDA 208398 – 505(b)(2)
8.4.5. Treatment Emergent Adverse Events and Adverse Reactions
8.4.5.1. Study GAI1001
There were no TEAEs reported in Study GAI1001.
8.4.5.2 Study GAI1002
Results are discussed in Section 8.5.1.
8.4.5.3 Study GAI3002
In Study GAI3002, 11% (44/396) of the subjects reported at least 1 TEAE (Table 14). The most
common TEAEs were reported in the Gastrointestinal Disorders SOC (14/396 [4%]) and General
Disorders and Administration Site Conditions SOC (11/396 [2.8%]). TEAEs reported in greater
than or equal to 5 subjects included pyrexia (11 [2.8%]), diarrhea (10 [2.5%]), lymphadenopathy
(8 [2.0%]), and cough (5 [1.3%]). There was one TEAE of epistaxis considered severe. The
remainder of TEAEs was mild or moderate in severity.
8.4.5.4 Study GAI3003
In Study GAI3003, the incidence of TEAEs in the double-blind phase was similar in the
mebendazole (9/144 [6.3%]) and placebo (8/140 [5.7%]) treatment groups (Table 14). The
most common TEAEs were reported in the Infections and Infestations SOC (mebendazole 3/144
[2.1%] versus placebo 4/140 [2.9%]). One TEAE occurred in more than one subject (abdominal
pain, n=2 [1.4%]). All TEAEs were mild or moderate in severity.
In the open label phase of the study, the incidence of TEAEs was higher in the subjects who
received mebendazole in the double-blind phase (6/141 [4.3%]) versus placebo (1/137 [0.7%]
(Table 15). The most common TEAEs were reported in the Gastrointestinal Disorders SOC
(3/278 [1.1%]). No TEAE occurred in more than one subject. All TEAEs were mild or moderate
in severity.

Clinical Review
NDA 208398 – 505(b)(2)
Table 14 Treatment-Emergent Adverse Events by Body System (GAI3002 and GAI3003

[Double-Blind Phase]) - Safety Population.

Clinical Review
NDA 208398 – 505(b)(2)
Table 15 Treatment-Emergent Adverse Events by Body System Open-Label Follow-Up Phase

(GAI3003) - Safety Population.
Reviewer Comment: Please see Section 8.7 for discussion about Applicant’s proposed labeling.

Clinical Review
NDA 208398 – 505(b)(2)
8.4.6. Laboratory Findings
No clinically significant changes in laboratory findings (hematology, chemistry and urinalysis)

were reported after study drug administration in Study GAI1001 and GAI1002. No clinical
laboratory assessments were conducted for Study GAI3002 and GAI3003.
8.4.7. Vital Signs
There were no clinically significant changes in vital signs (blood pressure, pulse, respiratory
rate, and temperature) over time for subjects in all four clinical studies (GAI1001, GAI1002,
GAI3002 and GAI3003). In Study GAI3002, three subjects reported a TEAE of increase in
respiratory rate on Study Day 1 (n=1) or Study Day 4 (n=2). All three TEAES were considered
mild in intensity.
8.4.8. Electrocardiograms (ECGs)
8.4.9. QT
8.4.10. Immunogenicity
Please see Section 8.9.1 regarding Stevens-Johnson Syndrome described in Postmarketing.
8.5. Analysis of Submission-Specific Safety Issues
8.5.1. Feeding Status
In Study GAI1002, the incidence of TEAEs was higher in the fasted state (5/16 [31.3%]) versus
the fed state (1/16 [6.3%]) (Table 24). There was no TEAE reported in more than two subjects
in either group.
In Study GAI3003, there was a higher incidence of TEAEs in the fasted state for both treatment
arms of the double-blind phase of the study [mebendazole, fed 4/85 [4.7%], fasted 5/59 [8.5%])
versus placebo, fed 2/81 [2.5%], fasted 6/59 [10.2%]) (Table 25).
In the open-label phase of the study, the incidence of TEAEs was similar in the fed (3/138
[2.2%]) and fasted (4/140 [2.9%]) states (Table 26). None of the TEAEs were reported in more
than 2 subjects in either the double-blind or open-label phase of the study in both the fed and
fasted groups.

Clinical Review
NDA 208398 – 505(b)(2)
Reviewer Comment: Despite findings described in the Clinical Pharmacology studies regarding
increased systemic exposures of the mebendazole chewable tablet, observed in comparison to
the non-chewable formulation in the fasted state (GAI1001) or with the concomitant ingestion
of a high fat meal (fed state) (GAI1002), there was no correlation between feeding status and a
particular TEAE. Furthermore, in the Phase 3 Study GAI3003, the incidence of TEAEs was higher
in the fasted state; however, there was no correlation between feeding status and a particular
TEAE. These findings are consistent with the published literature and suggest that the new
mebendazole 500 mg chewable tablet can be administered without regard to feeding status.
Published Clinical Pharmacology studies indicate that systemic bioavailability of a solid oral 500
mg dose of mebendazole is less than 10%. The majority of the dose of any mebendazole
formulation remains in the gastrointestinal tract where it is active against STH.
Systemic mebendazole exposures were examined through a bioavailability study (GAI1001) and
food effect study (GAI1002). Note that systemic mebendazole exposures for the previous 500
mg chewable formulation and the new 500 mg chewable formulation are similar.
Administration of the previous chewable formulation under fasted conditions resulted in about a
2-fold increase in mean systemic mebendazole exposure compared to the non-chewable
formulation. In addition, administration of the new mebendazole 500 mg chewable tablet to
adults with a high fat meal resulted in about a 2.4 to 4 fold increase in mean systemic
mebendazole exposures compared to fasted conditions. In Study GAI1002, the number of
subjects (n=16) enrolled are too small to draw any meaningful safety conclusions. The
distribution of TEAEs did not reveal a particular safety signal.
Please refer to the Clinical Pharmacology Review for additional details.
The literature reports increased mebendazole serum concentrations with meals. One published
study examined serum mebendazole concentrations in patients treated with 1 gram
mebendazole for hydatid disease. Serum mebendazole levels in 7 patients were higher when
administered with a ‘rich meal’ in comparison to administration on an empty stomach; however
these differences were not statistically significant.25
The clinical relevance of higher mebendazole exposures associated with a high fat meal is not
clear.
In the Phase 3 Study GAI3003, the incidence of TEAEs was higher in the fasted state for both the
mebendazole and placebo treatment arms. However, it should be noted that the total number
of TEAEs are small overall and it is difficult to make substantive conclusions (Double blind phase:
mebendazole, n=9 [6.3%] and placebo n=8 [5.7%]; Open-label phase: n=7 [2.5%]). TEAEs
occurring in both treatment arms of the fasted state in the double-blind phase included

Clinical Review
NDA 208398 – 505(b)(2)
‘abdominal distention’, ‘nasopharyngitis’ and ‘cough’. TEAEs occurring in both treatment arms
of the fed state included ‘abdominal pain’.
There are many published studies where higher doses or longer durations of mebendazole are
used. It is acknowledged that mebendazole formulations other than the proposed product were
used in these studies, and systemic absorptions may be different. Systemic exposures to
mebendazole and its metabolites at higher doses or longer durations (i.e. 40 mg/kg/day for 21
days, 2 grams 3 times a day) are similar to, or higher than, exposures observed with the new
chewable mebendazole 500 mg tablet.25, 26 In addition, higher mebendazole serum
concentrations with meals are noted when a higher than the proposed dose of mebendazole
(i.e. 1.5 gram, 10 mg/kg) is used for the treatment of hydatid disease.27, 28 Furthermore, in a
review of 121 patients, including children, receiving mebendazole treatment (30 to 100
mg/kg/day for 3 to 12 months) for hydatid disease, the most frequent side effects noted were
elevated SGOT and SGPT (n=14) and abdominal pain (n=14).29
Current labeling for the mebendazole 100 mg chewable tablet states that ‘the tablet may be
chewed, swallowed, or crushed and mixed with food’.8 In addition, the label states that ‘No
special procedures, such as fasting or purging, are required’.8
In the Applicant’s proposed labelling for the mebendazole 500 mg chewable tablets, the
Applicant does not make any recommendations regarding the administration of the drug during
fasting or fed conditions in Section 2, Dosage and Administration, of the label. In Section 12.3
Pharmacokinetics, the Applicant states that “Dosing with a high fat meal increases the
bioavailability of mebendazole, but has limited impact on the amount of drug in the
gastrointestinal tract.” This approach is reasonable.
8.5.2. Age
8.6.2.1 GAI 3002
The frequency of TEAEs was similar across all age groups in Study GAI3002 (<3 years [9/62,
14.5%], ш3 to ч 6 years [26/271 [9.6%], and ш7 to ч 10 years [9/63, 14.3%]) (Table 27).
TEAEs reported at greater than or equal to three percent in any age group included the
following:
o Less than 3 years: diarrhea 5/62 (8%), pyrexia 3/62 (5%)
o Three to 6 years: pyrexia 7/271 (3%)
o Seven to 10 years: lymphadenopathy 2/63 (3%)

Clinical Review
NDA 208398 – 505(b)(2)
groups. In the older pediatric subjects enrolled in Study GAI3003, mebendazole exposures were
similar to adult subjects in Study GAI1002. Please refer to the Clinical Pharmacology review for
additional details.
It should be noted that capillary fingerstick whole blood samples were obtained in the PK
substudy of Study GAI3003. Although results suggest that there is a reasonable correlation of
concentrations in capillary fingerstick whole blood and venous sampling methods, the
fingerstick sampling technique tended to overestimate mebendazole plasma concentrations.
The Applicant proposes that contamination during sample collection may have led to these
results. However, this reviewer disagrees and interprets the results as reported.
One published study examined plasma levels of mebendazole over a 6 hour period post-dose in
24 children with hydatid disease (age range 18 months to 16 years).30 Children received a 17
mg/kg dose of mebendazole with food (overall treatment 50 mg/kg daily in 3 divided doses for 9
months to 2 years). The mean (SD) mebendazole level 4 hours after dosing was 25.76 (9.81)
ng/ml and was similar to adults in the study. In addition, the mean Cmax values for the 3 to 7
and 7 to 16 year age groups in Study GAI3003 were similar to results of the published study. It
should be noted that the Cmax in the 1 to 3 year age group in Study GAI3003 was higher than the
results from the published study. A different formulation of mebendazole was used for the
published study and Study GAI3003.
Two additional studies show that systemic exposures to high-dose mebendazole and its
metabolite are higher in the youngest age group of Study GAI3003 compared to adults (Table
30).25, 26
The clinical relevance of the higher exposures noted in the youngest age groups is not clear.
In GAI3003, the frequency of TEAEs was similar between treatment arms across all age groups.
This observation is reassuring despite a potentially higher systemic mebendazole exposure in the
youngest age group.
Supportive evidence of safety of mebendazole in the youngest age group can be gathered from
published literature. For example, in a 1 year anti-helminthic drug study of children less than 24
months of age receiving mebendazole 500 mg chewable tablets (different than proposed
formulation) (n=317) or placebo (n=336), no differences between the incidence of adverse
effects in the 2 groups were observed 1 week following treatment.31 Although the study
collected data on a limited number of adverse events, the most frequent adverse events
recorded in both treatment arms were fever (mebendazole, 45/317 [12.1%], placebo 49/336
[14.5%]), cough (mebendazole, 32/317 [10.0%], placebo 37/336 [11.0%]) and diarrhea
(mebendazole, 18/317 [5.7%], placebo 12/336 [3.6%]).31

Clinical Review
NDA 208398 – 505(b)(2)
In addition, there is a recently published report of a randomized, multi-arm, placebo controlled

trial of single-dose mebendazole 500 mg tablet (crushed and mixed with fruit juice)
administered at different times and frequencies in children 12 to 24 months. There was no
difference in the frequency of serious or minor adverse events in the mebendazole treatment
groups (n=1,686) and the placebo group (n=1,760).32
Current labeling in the Pediatric Use Section of the mebendazole 100 mg chewable tablets
(b) (4)
states that “The drug has not been extensively studied in children under two years;
.8
The Applicant’s proposed labelling for the new mebendazole 500 mg chewable tablet, Section
8.4 Pediatric Use, states the following, “The safety and effectiveness of VERMOX™ Chewable
(b) (4) (b) (4)
500 mg tablets have been established in children years of age,
The Applicant’s approach is reasonable.
Please see Section 8.7 for information regarding safety data identified through Internal Clinical
Study Reports, which includes both pediatric and adult populations (age range, 0 to 70 years).
Please see Section 8.9.1 for additional information regarding Postmarketing concerns and
Pediatric labeling.
8.6.2.3 Postmarketing
The Applicant reports two cases of convulsions in infants exposed to mebendazole identified
through postmarketing.33, 34 Although a causal relationship cannot be established, the timing
between mebendazole intake and the convulsion is convincing.
A description of the two cases follows:

Case 1: A previously healthy 8-week-old Caucasian boy was prescribed mebendazole
(50 mg b.i.d. for 3 days) for prevention of pinworm infection.33 Twenty-four hours after
starting mebendazole, the infant developed transient staring attacks and arching of the
back. After 3 days’ medication, the patient developed generalized convulsions resulting
in status epilepticus and respiratory arrest. The infant was ventilated in an intensive
care unit, and received treatment with double-volume exchange transfusion.
Convulsions continued on the second day and treatment with phenobarbitone and
phenytoin was given. The subject was extubated, neurologically normal and discharged
from the hospital within days on a phenobarbitone taper within days. The child was
neurologically normal at the 6 month follow-up visit.

Clinical Review
NDA 208398 – 505(b)(2)
For labeling, the Applicant’s approach to include information about the risk of convulsions with
mebendazole exposure in children less than one year of age in Section 5.1 Warnings is
acceptable. There is limited data to support contraindicating (i.e. to never use) mebendazole in
children less than one year of age.
8.6. Safety Analyses by Demographic Subgroups
8.6.1 Sex
8.6.1.1 GAI3002
In Study GAI3002, the frequency of TEAEs was similar in females (19/ 190 [10.0%]) and males
(25/ 206 [12.1%]).
8.6.1.2 GAI3003
Overall, the frequency of TEAEs by sex was similar in both the mebendazole and placebo
treatment arms [mebendazole, female 6/75 [8.0%], male 7/69 [10.1%]) versus placebo, female
5/72 [6.9%], male 4/68 [5.9%])]. Similarly, during the double-blind phase of Study GAI3003, the
frequency of TEAEs by sex was similar in both the mebendazole and placebo treatment arms
[mebendazole, female 5/75 [6.7%], male 4/69 [5.8%]) versus placebo, female 4/72 [5.6%], male
4/68 [5.9%])]. No TEAEs were reported in more than one subject in either female or male
groups. Results were similar for the open label phase of the study (female, 3/146 [2.1%] versus
male, 4/132 [3.0%]).
Reviewer Comment: There is no discernible pattern of TEAEs and sex for Studies GAI3002 and
GAI3003.
8.6.2 Age
Please see Section 8.5.2.
8.7. Specific Safety Studies/Clinical Trials – Internal Clinical Studies
The Applicant completed an analysis of Adverse Drug Reactions from in-house confidential,
unpublished clinical trial reports for subjects treated with any dose of mebendazole for
intestinal helminth infections. Only studies with the following characteristics were included: 1.)
an available English translation; 2.) conducted in study populations corresponding to the
labeled indication or the labeled indication could not be determined; and 3.) study contained a
sample size of at least 40 subjects or sample size could not be determined. The Applicant
identified 67 reports of which 39 (including 6 double-blind placebo-controlled studies)
contained sufficient information to assess adverse drug reactions in the currently marketed

Clinical Review
NDA 208398 – 505(b)(2)
Reviewer Comment: Based on summary safety results of the Applicant’s 39 internal clinical
study reports (Table 17), this reviewer suggests that the following adverse reactions be
incorporated into Section 6.1, Adverse Reactions in Clinical Studies, of the Applicant’s proposed
label: ‘vomiting’, ‘diarrhea’, ‘nausea’, ‘abdominal pain’, ‘rash’ and ‘anorexia’.
In Section 6.1, Adverse Reactions in Clinical Studies, of the proposed label, the Applicant lists 4
adverse reactions reported by less than 1% of mebendazole-treated subjects in their 39 internal
studies. These adverse reactions include ‘abdominal discomfort’, ‘diarrhea’, ‘flatulence’, and
‘rash’. The Applicant does not include all adverse reactions which were reported in several
clinical studies, including ‘vomiting’, ‘diarrhea’, ‘nausea’, ‘abdominal pain’, and ‘anorexia’.
Furthermore, the Applicant does not provide sufficient data to support the incidence of TEAEs as
less than 1% in their Summary of Clinical Safety. Hence, this reviewer recommends removal of
the adverse reaction incidence in Section 6.1 of the label.
In addition, the Applicant proposes a statement that the safety profile of the mebendazole
chewable 500 mg tablet is consistent with the safety profile reported in the internal clinical
studies. This approach is acceptable if the Applicant incorporates labeling changes as proposed
by this reviewer.
8.8. Additional Safety Explorations
8.8.1. Human Carcinogenicity or Tumor Development
Previous genotoxicity studies indicate that mebendazole is not mutagenic or clastogenic.

Mebendazole is aneugenic in vitro in mammalian somatic cells at a threshold concentration of
115 ng/mL. In the youngest age group (< 3 years) and fed adults, the Applicant notes that the
aneugenic threshold is transiently exceeded. Lifetime studies in mice and rats showed an
absence of carcinogenicity with mebendazole exposure.
Reviewer Comment: The safety risk with single-dose administration is considered low with
regards to carcinogenicity or tumor development. This is further supported by post-marketing
data with repeated doses and prolonged treatment durations, where an increased risk for
carcinogenicity was not observed.
8.8.2. Human Reproduction and Pregnancy
Mebendazole has embryotoxic and teratogenic activity in pregnant rats at single oral doses as
low as 10 mg/kg (approximately 0.2 fold the MRHD, based on mg/m2).8 Doses up to 40 mg/kg
in rats (0.8 fold MRHD, based on mg/m2), given to males for 60 days and to females for 14 days
prior to gestation, were associated with maternal toxicity, but no effects on fetuses and
offspring were observed. Several large clinical studies suggest that there is no impact on
pregnancy outcome and short term mebendazole exposure.35-40

Clinical Review
NDA 208398 – 505(b)(2)
In the Applicant’s Periodic Benefit Risk Evaluation Report/ Periodic Safety Report (NDA 208398
SD7) covering 04 May 2015 through 03 May 2016 for mebendazole and mebendazole/
quinfamide, 7 cases reported drug exposure during pregnancy. Of these seven cases,
pregnancy outcomes were live birth (n=1) and not reported (n=4). One case concerned a 36-
year old female with a history of alcohol consumption who experienced a spontaneous
abortion. The remaining case reported a 27 year old female who experienced malaise when
treated with mebendazole for a helminthic infection during the eleventh week of her
pregnancy.36
The Applicant provides a review of several studies published in the literature. The Applicant
concludes that mebendazole use for treatment of STH infections in pregnant women after their
first trimester is safe and does not result in increased miscarriages, malformations, stillbirths,
early neonatal deaths and premature babies.35, 37, 38
Reviewer Comment: The published literature, including prospective pregnancy registries, case-
control retrospective cohorts and randomized-controlled studies, have reported no association
with mebendazole use and a potential risk of major birth defects or miscarriage (Table 31).
Furthermore, the WHO Recommendations on Preventive Chemotherapy in Human

Helminthiasis41 state the following: Several studies have failed to find a statistically significant
difference in the occurrence of congenital abnormalities between babies born to women treated
with single dose mebendazole or albendazole during pregnancy and those born to untreated
women. Similarly, no significant difference has been found in the occurrence of adverse birth
outcomes (abortion, stillbirth, birth defects) between women inadvertently exposed to
praziquantel, ivermectin, or the combination of ivermectin and albendazole (during large-scale
chemotherapy interventions), and women not exposed to the drugs. These studies include
approximately 6000 documented exposures to mebendazole, but the number of documented
exposures to the other anthelminthic drugs is much lower (approximately 50–200).
Regarding treatment of adolescent girls, women of reproductive age and pregnant women, the
WHO41 states the following: In areas where schistosomiasis and soil-transmitted helminthiasis
are endemic, risk–benefit analyses have revealed that the health advantages of treating women
of reproductive age and pregnant women far outweigh the risks to their health and to the
health of their babies. The benefits of treating pregnant women include reduced maternal
anemia and improved infant birth weight and survival. The proven benefits of antenatal
deworming in the absence of any evidence indicative of drug teratogenicity or embryotoxicity in
humans provides compelling evidence to support the treatment with albendazole or
mebendazole of women for STH after the first trimester of pregnancy.
The WHO41 goes on to recommend the following: For soil-transmitted helminthiasis, this

Clinical Review
NDA 208398 – 505(b)(2)
In the proposed label for the new mebendazole 500 mg chewable tablet, the Applicant describes
(b) (4)
the following adverse events in Section 10, Overdosage: ‘alopecia’,
‘hepatitis’, ‘agranulocytosis’, ‘neutropenia’, and ‘glomerulonephritis’. This is
approach is acceptable. ‘Reversible liver function disturbances’ could be changed to
‘Transaminase elevation’ or ‘Abnormal liver function tests’. The Applicant can consider including
‘glomerulonephritis’ in Section 6.2 Postmarketing Adverse Events Section of the label as well.
8.9. Safety in the Postmarket Setting
8.9.1. Safety Concerns Identified Through Postmarket Experience
The Applicant submitted a Periodic Benefit Risk Evaluation Report/ Periodic Safety Update
Report (PBRER/PSUR) (NDA 208398 SD7) covering 04 May 2015 through 03 May 2016 for
mebendazole and mebendazole/ quinfamide. Interval exposure to mebendazole and
mebendazole/quinfamide from 01 May 2015 to 30 April 2016 was approximately 35 million
treatment courses (Table 32). Approximately 4 million treatment courses were dispensed as a
500 mg chewable tablet (different than proposed) and 5 million treatment courses were
dispenses as an oral solution, suspension or syrup. Cumulative exposure to mebendazole and
mebendazole/ quinfamide from 1988 to 30 April 2016 was approximately 845 million treatment
(b) (4)
courses for all formulations (Table 33).
During the 04 May 2015 through 03 May 2016 reporting period, 47 spontaneous cases (46
initial, 1 follow-up) were identified involving pediatric patients whose age was between 2 and
18 years. One ‘case’ was a literature case of a study with 50 children receiving 300 mg ‘simple
dose’ mebendazole. Adverse events of nausea and vomiting (12% and 2%, respectively), were
reported. Of the remaining 46 cases, the most frequent MEDRA PT reported included
abdominal pain (n=7), diarrhea (n=6) and drug ineffective (n=6). Nausea was reported in 4
cases and vomiting was reported in 4 cases. There were no cases reporting use in children < 2
years during the reporting period.
Important identified risks, important potential risks and missing information were evaluated by
the Applicant (Table 18). No new safety information was identified during the most recent
PBRER/PSUR reporting period.

Clinical Review
NDA 208398 – 505(b)(2)
Table 18 Important Identified Risks, Important Potential Risks, and Missing Information
Source: NDA 208398 SD7, Periodic Benefit Risk Evaluation Report/ Periodic Safety Update
Report, Table 3.
Reviewer Comment: With the exception of ‘agranulocytosis’ and ‘glomerulonephritis’, the

Applicant adequately addresses important identified risks, important potential risks, and
missing information in the proposed label for the new mebendazole 500 mg chewable tablet.
The Applicant should also consider adding ‘agranulocytosis’ and ‘glomerulonephritis’ to Section
6.2, Postmarketing, of the label. In addition, ‘abdominal pain’ and ‘diarrhea’ should be included
in Section 6.1 Clinical Studies and deleted from Section 6.2 Postmarketing to avoid redundancy.
‘Convulsions’, ‘Hypersensitivity including anaphylactic reaction and anaphylactoid reaction’,

‘Exanthema’, Angioedema’, ‘Urticaria’, ‘Toxic epidermal necrolysis’, ‘Stevens-Johnson
Syndrome’, ‘Hepatitis’, ‘Abnormal liver function tests’, ‘Neutropenia’ are listed in Section 6.2 of
the Postmarketing Adverse Reactions section of the Applicant’s proposed label. The Warning
and Precautions Section of the proposed also label also includes the risk of convulsions in
children less than 1 year of age, as well as the risk of concomitant mebendazole use and serious
skin reactions.
This reviewer suggests inclusion of ‘agranulocytosis’ in Section 6.2 Postmarketing Adverse

Reactions Section of the label. The Warnings Section of the current label for the mebendazole
100 mg chewable tablet includes ‘agranulocytosis’ and ‘neutropenia’ associated with higher
doses and longer duration of treatment.8 However, it should be noted that ‘agranulocytosis’
and ‘neutropenia’ are not included in the Warnings and Precautions Section of the Applicant’s
proposed label for the new mebendazole 500 mg chewable tablet. Furthermore, in the
proposed label for the new mebendazole 500 mg chewable tablet, Section 6.2 Postmarketing
Adverse Reactions, includes ‘neutropenia’ but not ‘agranulocytosis’. Both adverse events are
well-described in the literature.42, 43, 45-49

Clinical Review
NDA 208398 – 505(b)(2)
This reviewer suggests inclusion of ‘glomerulonephritis’ in Section 6.2 Postmarketing Adverse

Reactions Section of the label. In the currently proposed label, the Applicant includes
‘glomerulonephritis in Section 10, Overdose, of the label. ‘Glomerulonephritis’ is not included in
the current label for the mebendazole 100 mg chewable tablet. ‘Glomerulonephritis’ has been
reported in the literature and in post-marketing reports and could be included in Section 6.1 of
the label.44 Mesangiocapillary glomerulonephritis has been described on pathology of patients
who had received mebendazole treatment for hydatid disease.44
(b) (4)
this reviewer recommends that these adverse events should be included in

Section 6.1 Clinical Studies and would not be repeated in Section 6.2 Postmarketing.
Choking is not included in the proposed label. This is acceptable. The intent of the new
mebendazole 500 mg chewable formulation is to minimize choking by its rapidly disintegrating
characteristics. There were no TEAEs of choking reported in GAI3002 and GAI3003. Cough was
reported in 5 subjects (1%) in GAI 3002, and equally in both arms of GAI3003 [mebendazole, n=1
(0.7%); placebo, n=2 (1.4%]).
The Applicant’s proposed label states that there is no data for pediatric patients under 1 year of
age in Section 8.4 Pediatric Use Section of the label. This is acceptable and supported by the
Applicant’s clinical trials. Please see Section 8.5.2 for additional information regarding
mebendazole exposure in children less than 1 year of age and labeling for Section 4
Contraindications and Section 5.1 Warnings.
In addition, the Applicant’s proposed label states that there insufficient data in subjects aged 65
years and over in Section 8.5 Geriatric Use Section of the label. This is acceptable. Furthermore,
the target population for mass drug administration programs for STH treatment is children.
The Applicant does not comment on patients with renal dysfunction in the proposed label. In
Section 12.3 Pharmacokinetics, the Applicant’s proposed label addresses the fact that higher
plasma levels of mebendazole levels may result in patients with impaired hepatic function,
impaired metabolism, or impaired biliary elimination.
8.10. Expectations on Safety in the Postmarket Setting
8.11. Additional Safety Issues From Other Disciplines
No additional safety issues were idenitifed by other disciplines. Please refer to discipline-
specific reviews for additional details.

Clinical Review
NDA 208398 – 505(b)(2)
(b) (4)
6.1 Adverse Reactions Reports adverse reactions Report the following: See Section
from Clinical Studies from 39 internal clinical ‘vomiting’, ‘diarrhea’, 8.7.
studies: ‘nausea’, ‘abdominal
(b) (4)
‘abdominal pain’, ‘rash’ and
‘diarrhea’, ‘flatulence’, and ‘anorexia’
‘rash’
(b) (4)
Remove
rom
Section 6.2
(b) (4)
Postmarketing.
(b) (4)
6.1 Adverse Reactions See Section
from Clinical Studies 8.7.
6.2 Adverse Reactions Lists the following adverse The following should be See Section
from Postmarketing reactions: added: 8.9.
‘Convulsions’, ‘Agranulocytosis’ and
‘Hypersensitivity including ‘Glomerulonephritis’
anaphylactic reaction and
anaphylactoid reaction’,
‘Exanthema’, Angioedema’,
‘Urticaria’, ‘Toxic epidermal
necrolysis’, ‘Stevens-
Johnson Syndrome’,
‘Hepatitis’, ‘Abnormal liver
(b) (4)
tests’,
‘Neutropenia’
8.1 Pregnancy Risk summary, clinical Changes incorporated See Section
considerations, human per DPMH consult to 8.8.2.
data, and animal data reflect PLLR.
described.
8.2 Lactation Risk summary described. Changes incorporated See Section
per DPMH consult to 8.8.2.
reflect PLLR.
(b) (4)
10 Overdosage Lists the following adverse ‘ See Section
reactions: could be 8.8.4.
‘alopecia’, ‘reversible (b) (4) changed to

Clinical Review
NDA 208398 – 505(b)(2)
(b) (4)
‘Transaminase elevation’
‘hepatitis’, or ‘Abnormal liver
(b) (4)
‘agranulocytosis’, tests’.
‘neutropenia’, and
‘glomerulonephritis’.
14.1 Clinical Studies Describes clinical trial data Suggest additional See Section
for Trichuris trichiura section for mixed species 7.2.3.
(whipworm) and/or Ascaris infection.
lumbricoides (large
roundworm)
14.1 Infestations with Arithmetic means for egg Displaying data using See Section
Trichuris trichiura count reduction rates are geometric means. 6.2.2.
(whipworm) and/or used.
Ascaris
lumbricoides (large
roundworm) in
Pediatric Patients (b) (4)
General Use of the term Suggest using ‘infection’
(b) (4)
to denote STH to denote STH infections
infections.

Clinical Review
NDA 208398 – 505(b)(2)
(b) (4)
10.2. Patient Labeling
A separate patient instruction sheet is not required.
Section 17 Patient Counseling Information, includes the following: 1. Recommends that the
tablet be chewed before swallowing; 2. Provides instructions on adding water to turn the
chewable tablet into semi-solid mass if the patient cannot chew; 3. Advises the patient to not
swallow the tablet whole; 4. Explains that the drug may be taken with or without food; and 5.
Cautions against the concomitant use of metronidazole.
10.3. Nonprescription Labeling
11Risk Evaluation and Mitigation Strategies (REMS)
A REMS is not required. Given the known safety profile of the various mebendazole
formulations, the risks for the new mebendazole 500 mg chewable tablet can be managed
through labeling.
12Postmarketing Requirements and Commitments
No post-marketing requirements or commitments are recommended.

Clinical Review
NDA 208398 – 505(b)(2)
13Appendices
13.1. References
1. Organization WH. Soil-transmitted Helminth Infections Fact Sheet. 2016.

http://www.who.int/mediacentre/factsheets/fs366/en/ (accessed April 25 2016).
2. Organization WH. Helminth control in school age children: a guide for managers of
control programmes - 2nd edition, 2011.
3. Prevention USCfDCa. Parasites - Soil-transmitted Helminths (STHs). 2013.
http://www.cdc.gov/parasites/sth/ (accessed April 25 2016).
4. Organization WH. Controlling disease due to helminth infections, 2002.
5. Kappagoda S, Singh U, Blackburn BG. Antiparasitic therapy. Mayo Clinic proceedings
2011; 86(6): 561-83.
6. Keiser J, Utzinger J. Efficacy of current drugs against soil-transmitted helminth
infections: systematic review and meta-analysis. Jama 2008; 299(16): 1937-48.
7. Treatment Guidelines from The Medical Letter: Drugs for Parasitic Infections. The
Medical Letter 2013; 11 (Suppl).
8. Medicine USNLo. Mebendazole - mebendazole tablet, chewable. October 12, 2012
2012. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c338415f-41e0-071d-8c51-
a80a02ebf2cd (accessed June 16, 2016 2016).
9. Organization WH. Soil-transmitted helminthiases: eliminating soil-transmitted
helminthiases as a public health problem in children: progress report 2001-2010 and strategic
plan 2011-2020., 2012.
10. Administration USFaD. Draft Guidance for Industry: Quality Attribute Considerations for
Chewable Tablets, 2016.
11. Keiser J, Utzinger J. The drugs we have and the drugs we need against major helminth
infections. Advances in parasitology 2010; 73: 197-230.
12. Levecke B, Montresor A, Albonico M, et al. Assessment of anthelmintic efficacy of
mebendazole in school children in six countries where soil-transmitted helminths are endemic.
PLoS neglected tropical diseases 2014; 8(10): e3204.
13. Steinmann P, Utzinger J, Du ZW, et al. Efficacy of single-dose and triple-dose
albendazole and mebendazole against soil-transmitted helminths and Taenia spp.: a
randomized controlled trial. PLoS One 2011; 6(9): e25003.
14. Organization WH. Report of the WHO Actions Against Worms Newsletter. 2007; (8).
15. Bethony J, Brooker S, Albonico M, et al. Soil-transmitted helminth infections: ascariasis,
trichuriasis, and hookworm. Lancet 2006; 367(9521): 1521-32.
16. Diawara A, Schwenkenbecher JM, Kaplan RM, Prichard RK. Molecular and biological
diagnostic tests for monitoring benzimidazole resistance in human soil-transmitted helminths.
The American journal of tropical medicine and hygiene 2013; 88(6): 1052-61.

Clinical Review
NDA 208398 – 505(b)(2)
17. Abadi K. Single dose mebendazole therapy for soil-transmitted nematodes. The
American journal of tropical medicine and hygiene 1985; 34(1): 129-33.
18. Albonico M, Bickle Q, Ramsan M, Montresor A, Savioli L, Taylor M. Efficacy of
mebendazole and levamisole alone or in combination against intestinal nematode infections
after repeated targeted mebendazole treatment in Zanzibar. Bulletin of the World Health
Organization 2003; 81(5): 343-52.
19. Charoenlarp P, Waikagul J, Muennoo C, Srinophakun S, Kitayaporn D. Efficacy of single-
dose mebendazole, polymorphic forms (b) (4) C, in the treatment of hookworm and Trichuris
infections. The Southeast Asian journal of tropical medicine and public health 1993; 24(4): 712-
6.
20. De Clercq D, Sacko M, Behnke J, Gilbert F, Dorny P, Vercruysse J. Failure of mebendazole
in treatment of human hookworm infections in the southern region of Mali. The American
journal of tropical medicine and hygiene 1997; 57(1): 25-30.
21. Sacko M, De Clercq D, Behnke JM, Gilbert FS, Dorny P, Vercruysse J. Comparison of the
efficacy of mebendazole, albendazole and pyrantel in treatment of human hookworm
infections in the southern region of Mali, West Africa. Transactions of the Royal Society of
Tropical Medicine and Hygiene 1999; 93(2): 195-203.
22. Flohr C, Tuyen LN, Lewis S, et al. Low efficacy of mebendazole against hookworm in
Vietnam: two randomized controlled trials. The American journal of tropical medicine and
hygiene 2007; 76(4): 732-6.
23. Albonico M, Bickle Q, Haji HJ, et al. Evaluation of the efficacy of pyrantel-oxantel for the
treatment of soil-transmitted nematode infections. Transactions of the Royal Society of Tropical
Medicine and Hygiene 2002; 96(6): 685-90.
24. Larocque R, Casapia M, Gotuzzo E, et al. A double-blind randomized controlled trial of
antenatal mebendazole to reduce low birthweight in a hookworm-endemic area of Peru.
Tropical medicine & international health : TM & IH 2006; 11(10): 1485-95.
25. Bekhti A. Serum concentrations of mebendazole in patients with hydatid disease.
International journal of clinical pharmacology, therapy, and toxicology 1985; 23(12): 633-41.
26. Braithwaite PA, Roberts MS, Allan RJ, Watson TR. Clinical pharmacokinetics of high dose
mebendazole in patients treated for cystic hydatid disease. Eur J Clin Pharmacol 1982; 22(2):
161-9.
27. Braithwaite PA, Allan RJ, Dawson M, Roberts MS, Watson TR. Cyst and host tissue
concentrations of mebendazole in patients undergoing surgery for hydatid disease. The Medical
journal of Australia 1983; 2(8): 383-4.
28. Munst GJ, Karlaganis G, Bircher J. Plasma concentrations of mebendazole during
treatment of echinococcosis: preliminary results. European journal of clinical pharmacology
1980; 17(5): 375-8.
29. Teggi A, Lastilla MG, De Rosa F. Therapy of human hydatid disease with mebendazole
and albendazole. Antimicrobial agents and chemotherapy 1993; 37(8): 1679-84.
30. Toppare MF, Gocmen A, Kiper N. Plasma levels of mebendazole in children with hydatid
disease. Annals of tropical paediatrics 1992; 12(4): 441-3.

Clinical Review
NDA 208398 – 505(b)(2)
31. Montresor A, Stoltzfus RJ, Albonico M, et al. Is the exclusion of children under 24
months from anthelmintic treatment justifiable? Transactions of the Royal Society of Tropical
Medicine and Hygiene 2002; 96(2): 197-9.
32. Joseph SA, Montresor A, Casapia M, Pezo L, Gyorkos TW. Adverse Events from a
Randomized, Multi-Arm, Placebo-Controlled Trial of Mebendazole in Children 12-24 Months of
Age. The American journal of tropical medicine and hygiene 2016.
33. el Kalla S, Menon NS. Mebendazole poisoning in infancy. Annals of tropical paediatrics
1990; 10(3): 313-4.
34. Crabbe RA, WK. Mebendazole and seizures in children, February 1991.
35. de Silva NR, Sirisena JL, Gunasekera DP, Ismail MM, de Silva HJ. Effect of mebendazole
therapy during pregnancy on birth outcome. Lancet 1999; 353(9159): 1145-9.
36. Diav-Citrin O, Shechtman S, Arnon J, Lubart I, Ornoy A. Pregnancy outcome after
gestational exposure to mebendazole: a prospective controlled cohort study. American journal
of obstetrics and gynecology 2003; 188(1): 282-5.
37. Acs N, Banhidy F, Puho E, Czeizel AE. Population-based case-control study of
mebendazole in pregnant women for birth outcomes. Congenital anomalies 2005; 45(3): 85-8.
38. Gyorkos TW, Larocque R, Casapia M, Gotuzzo E. Lack of risk of adverse birth outcomes
after deworming in pregnant women. The Pediatric infectious disease journal 2006; 25(9): 791-
4.
39. Torp-Pedersen A, Jimenez-Solem E, Cejvanovic V, Poulsen HE, Andersen JT. Birth
outcomes after exposure to mebendazole and pyrvinium during pregnancy - A Danish
nationwide cohort study. Journal of obstetrics and gynaecology : the journal of the Institute of
Obstetrics and Gynaecology 2016: 1-6.
40. Satya DD, Nandini L. Effects of deworming during pregnancy on maternal and perinatal
outcomes: a randomized controlled trial. Res J Pharm Biol Chem Sci 2015; 6(1): 1521-6.
41. Organization WH. Preventive chemotherapy in human helminthiasis : coordinated use of
anthelminthic drugs in control interventions : a manual for health professionals and programme
managers, 2006.
42. Schantz PM, Van den Bossche H, Eckert J. Chemotherapy for larval echinococcosis in
animals and humans: report of a workshop. Zeitschrift fur Parasitenkunde 1982; 67(1): 5-26.
43. Levin MH, Weinstein RA, Axelrod JL, Schantz PM. Severe, reversible neutropenia during
high-dose mebendazole therapy for echinococcosis. Jama 1983; 249(21): 2929-31.
44. Kung'u A. Glomerulonephritis following chemotherapy of hydatid disease with
mebendazole. East African medical journal 1982; 59(6): 404-9.
45. Fernandez-Banares F, Gonzalez-Huix F, Xiol X, et al. Marrow aplasia during high dose
mebendazole treatment. The American journal of tropical medicine and hygiene 1986; 35(2):
350-1.
46. Braithwaite PA, Thomas RJ, Thompson RC. Hydatid disease: the alveolar variety in
Australia. A case report with comment on the toxicity of mebendazole. The Australian and New
Zealand journal of surgery 1985; 55(5): 519-23.

Clinical Review
NDA 208398 – 505(b)(2)
47. Davidson RA. Issues in clinical parasitology: the management of hydatid cyst. The
American journal of gastroenterology 1984; 79(5): 397-400.
48. Kammerer WS, Schantz PM. Long term follow-up of human hydatid disease
(Echinococcus granulosus) treated with a high-dose mebendazole regimen. The American
journal of tropical medicine and hygiene 1984; 33(1): 132-7.
49. Miskovitz PF, Javitt NB. Leukopenia associated with mebendazole therapy of hydatid
disease. The American journal of tropical medicine and hygiene 1980; 29(6): 1356-8.

Clinical Review
NDA 208398 – 505(b)(2)
13.2. Financial Disclosure
The Applicant adequately disclosed financial arrangements with clinical investigators.
Covered Clinical Study (Name and/or Number): MEBENDAZOLGAI3003
Was a list of clinical investigators provided: Yes No (Request list from

Applicant)
Total number of investigators identified: 3 Principal Investigators, 9 Sub-Investigators
Number of investigators who are Sponsor employees (including both full-time and part-time
employees): 0
Number of investigators with disclosable financial interests/arrangements (Form FDA 3455):

0
If there are investigators with disclosable financial interests/arrangements, identify the
number of investigators with interests/arrangements in each category (as defined in 21 CFR
54.2(a), (b), (c) and (f)):
Compensation to the investigator for conducting the study where the value could be
influenced by the outcome of the study: Not applicable
Significant payments of other sorts: Not applicable
Proprietary interest in the product tested held by investigator: Not applicable
Significant equity interest held by investigator in S
Sponsor of covered study: Not applicable
Is an attachment provided with details Yes No (Request details from
of the disclosable financial Applicant)
interests/arrangements: Not applicable
Is a description of the steps taken to Yes No (Request information

minimize potential bias provided: from Applicant)
Not applicable
Number of investigators with certification of due diligence (Form FDA 3454, box 3)
The Applicant’s Senior Financial Director, Ryan Koors, submits a Form 3454 for all 3 Primary
Investigators and 9 Sub-Investigators.
Is an attachment provided with the Yes No (Request explanation
reason: from Applicant)

Clinical Review
NDA 208398 – 505(b)(2)
renal toxicity
Levamisole FDA-Approved for Not approved Single dose, Single-dose Not evaluated in None.
veterinary treatment of for STH weight-based levamisole randomized
adult nematode dosing less placebo
infections in cattle and efficacious for controlled trial
sheep. hookworm at recommended
6
than single- doses.
dose
6
albendazole.
Pyrantel FDA-Approved for over- Not approved Hookworm: Single-dose Occasional: GI None.
pamoate the-counter use for for other STH 11 mg/kg pyrantel disturbance,
Enterobius vermicularis base (max 1 pamoate less headache,
(pinworm) treatment. g) po daily x efficacious for dizziness, rash,
3 days hookworm fever
than single-
dose
6
albendazole.
(b) (4)
Ivermectin FDA approved for Not approved Not Occasional: Not used for
Strongyloidiasis, for STH efficacious Cutaneous, WHO STH
onchocerciasis against systemic or control
hookworm. ophthalmologic programs.
Trichuris: 200 reactions when
mcg/kg/d used as
orally x 3 microfilaricidal
days treatment.
Rare:
Hypotension

Clinical Review
NDA 208398 – 505(b)(2)
13.4. Overall Study Design for GAI3003
Figure 1 Overall Study Design for GAI3003.
Source: NDA 208398, Module 2.7.3, Summary of Clinical Efficacy, Figure 1.

Clinical Review
NDA 208398 – 505(b)(2)
13.5. Time and Events Schedule for GAI3003
Table 21 Time and Events Schedule for GAI3003
Source: NDA 208398, Clinical Protocol Amendment INT-4 MEBENDAZOLGAI3003, Time and
Events Schedule.

Clinical Review
NDA 208398 – 505(b)(2)
13.8. Treatment Emergent Adverse Events by System Organ Class and

Dictionary-derived Terms for Study GAI1002 - Safety Population
Table 24 Treatment Emergent Adverse Events by System Organ Class and Dictionary-derived
Terms for Study GAI1002 - Safety Population

Clinical Review
NDA 208398 – 505(b)(2)
13.9. Treatment Emergent Adverse Events by Food State for Study

GAI3003 Double Blind Phase - Safety Population
Table 25 Treatment Emergent Adverse Events by Food State for Study GAI1003 Double Blind
Phase - Safety Population.

Clinical Review
NDA 208398 – 505(b)(2)
13.10. Treatment Emergent Adverse Events by Food State for Study

GAI3003 Open Label Phase - Safety Population
Table 26 Treatment Emergent Adverse Events by Food State for Study GAI1003 Open Label
Phase - Safety Population.

Clinical Review
NDA 208398 – 505(b)(2)
13.12. Treatment Emergent Adverse Events by Age for Study GAI1003

Double-Blind Phase - Safety Population
Table 28 Treatment Emergent Adverse Events by Age for Study GAI3003 Double Blind Phase -
Safety Population.

Clinical Review
NDA 208398 – 505(b)(2)
13.13. Treatment Emergent Adverse Events by Age for Study GAI1003

Open Label Phase - Safety Population
Table 29 Treatment Emergent Adverse Events by Age for Study GAI3003 Open Label Phase -
Safety Population.
Source: NDA 208398, Module 2.7.2, Summary of Clinical Pharmacology Studies, Appendix 9.

Clinical Review
NDA 208398 – 505(b)(2)
13.14. Systemic Exposure (AUC) to Mebendazole and its Metabolites –

Clinical Studies and Literature
Table 30 Systemic Exposure (AUC) to Mebendazole and its Metabolites After Single or
Repeated Oral Doses
Source: NDA 208398, Module 2.7.2, Summary of Clinical Pharmacology, Table 23.

Clinical Review
NDA 208398 – 505(b)(2)
13.16. Interval and Cumulative Postmarketing Exposure
Table 32 Exposure to mebendazole and mebendazole/quinfamide (01 May 2015 to 30 April

2016)
Report, Table 2.
Table 33 Exposure to mebendazole and mebendazole/quinfamide (1988 to 30 April 2016)
Report, Table 3.

Clinical Review
NDA 208398 – 505(b)(2)

---------------------------------------------------------------------------------------------------------
This is a representation of an electronic record that was signed
electronically and this page is the manifestation of the electronic
signature.
---------------------------------------------------------------------------------------------------------
/s/
----------------------------------------------------
SHERAL S PATEL
10/06/2016
HALA H SHAMSUDDIN
10/06/2016

CIS Page 2 NDA 208398 (Vermox®)
II. BACKGROUND
Mebendazole is an anti-helminthic indicated for the treatment of gastrointestinal
infestation by the whipworm Trichuris trichiura, the roundworm Ascaris lumbricoides,
and/or the hookworms Ancylostoma duodenale and Necator americanus. Under an
orphan designation (granted 2014) for neglected tropical diseases, Janssen Research
and Development (JRD) developed a chewable formulation of mebendazole (Vermox®) to
improve treatment compliance in young children. The pivotal study GAI3003 was a
randomized, double-blind, placebo-controlled trial in 295 children (age 1-16 years)
completed over nine months (2015) at three CI sites in areas endemic for soil-transmitted
helminth (STH) infestation (two in Ethiopia, one in Rwanda).
Study GAI3003: A Double-Blind, Randomized, Multi-Center, Parallel-Group, Placebo-
Controlled Study to Evaluate the Efficacy and Safety of a Single Dose of a 500-mg
Chewable Tablet of Mebendazole in the Treatment of Soil-Transmitted Helminth
Infestations (Ascaris lumbricoides and Trichuris trichiura) in Pediatric Subjects
The primary study objective was to compare chewable mebendazole (single 500 mg
tablet) with placebo in clearing (as assessed at end of blinded period) Ascaris
lumbricoides and Trichuris trichiura infestations (co-primary efficacy endpoints/analyses
of cure rates). The study included five visits: (1) screening, collection and examination of
stool sample for STH egg counts (Kato-Katz method); (2) Day 1, randomization and
single-dose oral treatment with either chewable mebendazole or matching placebo; (3)
Day 19, end of blinded period, repeat collection and examination of stool sample for STH
egg counts followed by open-label active therapy; (4) Day 20 (day after Visit 3), collection
of samples for pharmacokinetic evaluation; and (5) Day 26 (one week after Visit 3), end of
open-label follow-up, final safety evaluations. This study was audited on-site at GCP
inspection of the largest of the three participating CI sites (156 of 295 subjects, 53%).
III. INSPECTION OUTCOME: Audit of Study GAI3003 at Site 251002

Clinical Investigator Site Site / Enrollment Outcome
Netsanet Workenh Gidi, M.D.

Site 251002 September 19-21, 2016
Jimma University Hospital
156 subjects NAI
Jimma, Ethiopia
NAI: No Action Indicated (no significant deviations from GCP regulations)

The establishment inspection report (EIR) has not been received from the field office and the
inspection outcome shown is based on preliminary communication with the field investigator. At
EIR receipt and review, an addendum may be forwarded to the review division if new significant
findings are discovered; otherwise, OSI’s written post-inspection correspondence with the CI
(copied to review division) indicates EIR review completion with confirmation of the findings as
reported in this clinical inspection summary (CIS).
The Request for Clinical Inspections lists three CI sites, of which the two in Ethiopia were to be
inspected. Site 251001 (Emias Diro; Gondar, Ethiopia) could not be inspected due to travel
restriction to Gondar, Ethiopia.

Netsanet Workenh Gidi, M.D.

Site 251002: 4175 subjects were screened, 156 were enrolled, 8 were withdrawn, and
148 completed the study. Case records were reviewed for all enrolled subjects, including
detailed review for efficacy evaluations and adverse event monitoring.
No significant GCP deficiencies were observed and a Form FDA 483 was not issued.
Verbal discussion included not rigorously following the quality control procedures in
determining STH egg counts (three subjects), which appeared minor and unlikely to be
significant to the study outcome.
Study conduct appeared GCP-compliant overall, including sponsor oversight of study
conduct. All audited data were adequately verifiable against source records and CRFs.
The data from this CI site appear reliable as reported in the sNDA.
{See appended electronic signature page}

John Lee, M.D.
Good Clinical Practice Assessment Branch
Division of Clinical Compliance Evaluation
Office of Scientific Investigations
CONCURRENCE: {See appended electronic signature page}

Janice K. Pohlman, M.D., M.P.H.
Team Leader
{See appended electronic signature page}

Kassa Ayalew, M.D., M.P.H.
Branch Chief
CC:
DAIP / Division Director / Sumathi Nambiar
DAIP / Clinical Team Leader / Hala Shamsuddin
DAIP / Medical Officer / Sheral Patel
DAIP / Regulatory Health Project Manager / Alison Rodgers

OSI / Office Director / David Burrow

OSI / DCCE / Division Director / Ni Khin
OSI / DCCE / GCPAB / Branch Chief / Kassa Ayalew
OSI / DCCE / GCPAB / Team Leader / Janice Pohlman
OSI / DCCE / GCPAB / Medical Officer / John Lee
OSI / DCCE / GCPAB / Program Analyst / Yolanda Patague
OSI / Database Project Manager / Dana Walters

---------------------------------------------------------------------------------------------------------
signature.
---------------------------------------------------------------------------------------------------------
/s/
----------------------------------------------------
JONG HOON LEE
10/03/2016
JANICE K POHLMAN
10/03/2016
KASSA AYALEW
10/03/2016

Request for Priority Review Designation
NDA Supporting Document Number: NDA 208398 SD1

Reference IND: IND 115959
Sponsor: Janssen Pharmaceutical Research & Development,
LLC
Drug: VERMOX® (mebendazole) 500 mg chewable tablet
(b) (4)
Proposed Indication: Single dose for the treatment of
(b) (4)
gastrointestinal by Trichuris trichiura
(whipworm), Ascaris lumbricoides (large
(b) (4)
roundworm),
Correspondence Date: April 19, 2016

Date Received / Agency: April 19, 2016
Date Review Completed: April 25, 2016
Reviewer: Sheral S. Patel, M.D. (DAIP/OAP/OND/CDER)
Team Leader: Hala Shamsuddin, M.D. (DAIP/OAP/OND/CDER)
Materials Reviewed: Request for Priority Review Designation
1. Introduction
The Sponsor submits an NDA application for VERMOX Chewable (mebendazole) 500 mg
chewable tablets seeking the indication of treatment of soil transmitted helminths in adults and
(b) (4)
pediatrics and concurrently submits a request for designation of
Priority Review.
2. Recommendations
This reviewer recommends granting the Sponsor’s request for Priority Review.
Soil transmitted helminth infections are considered a serious condition. The mebendazole 500
mg chewable provides significant improvement over the mebendazole 100 mg chewable tablet
for the following reasons.
x The mebendazole 500 mg chewable tablet allows for administration to a broader age
range of children, a special population. The mebendazole 500 mg chewable tablet has
been studied in children as young as 1 year of age, while the currently approved
mebendazole 100 mg chewable tablet has only been studied in children greater than 2
years of age.
x The mebendazole 500 mg chewable tablet is a single dose regimen which improves
compliance over the mebendazole 100 mg tablet dosing regimen (100 mg BID for 3
days), potentially contributing to improved effectiveness.
x The rapidly disintegrating formulation allows for dosing to individuals who may have
difficulty chewing or swallowing the 100 mg tablet, such as young children, potentially
minimizing adverse events such as choking.
1
3. Drug Product
Mebendazole is a synthetic broad-spectrum anthelmintic agent for oral administration belonging

to the class of benzimidazole derivatives. Mebendazole has low systemic bioavailability, with
90% of the drug remaining in the gastrointestinal tract, where it exerts activity against soil-
transmitted helminths (STH).
The proprietary name (VERMOX Chewable [mebendazole] 500 mg Tablets) was conditionally
accepted by the Agency on 18 December 2015.
Orphan Drug Designation was granted on 08 September 2014.
4. Proposed Indication
Mebendazole (Vermox) 100 mg chewable tablets were approved on 28 June 1974 (NDA 17-
481) for the treatment of T. trichiura (whipworm), A. lumbricoides (large roundworm), Enterobius
vermicularis (pinworm), and A. duodenale and N. americanus (hookworm) in single or mixed
(b) (4)
In 2006, marketing in the US was discontinued for commercial reasons. However,
the NDA has not been withdrawn and annual safety reporting continues.
The proposed indications for VERMOX Chewable (mebendazole) 500-mg chewable tablets are
treatment of single or mixed gastrointestinal infestations by Trichuris trichiura (whipworm);
(b) (4)
Ascaris lumbricoides (large roundworm); and Ancylostoma duodenale
Reviewer comment: The Sponsor is not seeking an indication for the treatment of Enterobius
vermicularis (pinworm), which is approved for the mebendazole 100 mg chewable tablets.
5. Justification for Priority Review
According to the FDA Guidance for Industry: Expedited Programs for Serious Conditions –
Drugs and Biologics, qualifying criteria for priority review include: 1
1. An application (original or efficacy supplement) for a drug that treats a serious

condition
AND,
2. If approved, would provide a significant improvement in safety or effectiveness
This review will focus on the justification provided for the two aforementioned criteria to
determine priority review.
5.1 Whether soil transmitted helminthiasis is a serious condition, and whether

mebendazole treats this condition
2
A serious disease or condition is defined in the expanded access regulations as follows:1
. . . a disease or condition associated with morbidity that has

substantial impact on day-to-day functioning. Short-lived and self-
limiting morbidity will usually not be sufficient, but the morbidity
need not be irreversible if it is persistent or recurrent. Whether a
disease or condition is serious is a matter of clinical judgment,
based on its impact on such factors as survival, day-to-day
functioning, or the likelihood that the disease, if left untreated, will
progress from a less severe condition to a more serious one.
Soil transmitted helminth (STH) infections are considered a neglected tropical disease. STH
infections are caused by four main species of parasitic worms (Trichuris trichiura (whipworm);
(b) (4)
Ascaris lumbricoides (large roundworm); and Ancylostoma duodenale
. In areas of poor sanitation, people are infected through soil contaminated with
helminth eggs passed through human feces.
According to the World Health Organization (WHO), STH infections are found in more than 1.5
billion people, or 24% of the world’s population.2 Furthermore, there are over 270 million
preschool-age children and over 600 million school-age children living in areas where these
parasites are intensively transmitted.2
Morbidity from STH infections is associated with worm burden. Clinical presentation can range
from asymptomatic to intestinal manifestation (diarrhea, abdominal pain), malaise, and
weakness.3, 4 Impaired cognitive and physical development can occur with soil-transmitted
infections in children.3, 4 Hookworm infection specifically can lead to chronic intestinal blood loss
and anemia.
In addition, STH infections lead to impaired nutritional status through worms feeding on host
tissue, including blood, and increased malabsorption of nutrients in the host.3, 4 Furthermore,
infected individuals may experience gastrointestinal symptoms, such as loss of appetite,
diarrhea, and abdominal pain, which can lead to decreased food intake.
The WHO recommends control of STH infections to decrease morbidity through periodic
treatment of at-risk individuals living in endemic areas.2 At-risk individuals include preschool
children, school-age children, women of childbearing age (including pregnant women in the
second and third trimesters and breastfeeding women), as well as adults in certain high-risk
occupations such as tea-pickers or miners. Periodic treatment decreases worm burden, which
can decrease morbidity.
Mebendazole 100 mg chewable tablet is the only FDA approved therapy for STH.
Reviewer comment: Periodic treatment to reduce worm burden is especially important in the
pediatric population. Children with high burdens of intestinal helminths will experience long term
cognitive and physical delays if not treated.The proposed indication, for which the Sponsor’s
drug is intended to treat, meets the criteria for a serious condition.
3
5.2 Significant improvement in safety or effectiveness over other available FDA-approved
therapies
According to the Guidance, the proposed drug should be a significant improvement over
available therapies in the safety or effectiveness of the treatment, prevention, or diagnosis of a
serious condition.1
The approved therapy for the treatment of STH in the United States is mebendazole 100 mg
chewable tablet, which is administered bid for 3 days. The label states that 100 mg tablets have
not been studied in children less than 2 years of age.
A 500 mg solid oral mebendazole tablet, used for single dose administration to treat STH, is not
available in the United States. Although the solid oral tablet can be crushed and administered
with a small amount of potable water, if available, for children less than 5 years old, this is not a
preferred method for several reasons: 1.) additional work required for crushing the tablet, 2.)
unpleasant taste of the medication, 3.) possible choking hazard if the medication is not
completely crushed, and 4.) chance of insufficient dosing if part of the medication is lost.
Given these reasons, the WHO recommends that only chewable deworming tablets should be
given to children under 5 years old, and that chewable tablets be crushed and mixed with water
in children under 3 years old. The WHO recommends a 500-mg chewable dose for all ages 1
year, with no adjustment in dosage needed based on age, weight or surface area.5
The Sponsor’s proposed 500 mg chewable tablet would be administered as a single dose. It is
a rapidly disintegrating formulation which turns into a soft semi-solid mass when mixed with a
small amount of water. In addition, the 500 mg chewable tablet has been studied in children as
young as 1 year old.
The Sponsor reports results from a Phase 3 study (GAI3003) which showed that a single dose
of mebendazole 500 mg chewable tablet is more effective that placebo in the treatment of A.
lumbricoides (83% vs. 11%, respectively) and T. trichura (34% vs. 7%, respectively) in pediatric
subjects as young as one year. The Sponsor reports that results from the 712 subjects in the 4
studies submitted for the application for the mebendazole 500 mg chewable tablets showed a
safety profile consistent with what has been reported in the literature and in postmarketing
surveillance in adults and children.
Reviewer comment: The Sponsor’s proposed mebendazole 500 mg chewable tablets meet
the criteria for significant improvement in safety or effectiveness. It offers several improvements
over existing therapy including:
1. Improved patient compliance by single dose administration (which may indirectly
contribute to improved efficacy)
2. Ability to administer drugs to individuals who may have difficulty chewing a tablet, such as
young children (possibility of less adverse events such as choking)
3. Potential to treat children as young as 1 year of age (special populations)
4
6. References
1. U.S. FDA Guidance for Industry: Expedited Program for Serious Conditions - Drugs and Biologics,
2014. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
2. World Health Organization. Soil-transmitted Helminth Infections Fact Sheet. 2016.
http://www.who.int/mediacentre/factsheets/fs366/en/ (accessed April 25 2016).
3. World Health Organization. Soil-transmitted helminthiases: eliminating soil-transmitted
helminthiases as a public health problem in children: progress report 2001-2010 and strategic plan
2011-2020., 2012.
4. U.S. Centers for Disease Control and Prevention. Parasites - Soil-transmitted Helminths (STHs).
2013. http://www.cdc.gov/parasites/sth/ (accessed April 25 2016).
5. World Health Organization. Controlling disease due to helminth infections, 2002.
5
---------------------------------------------------------------------------------------------------------
signature.
---------------------------------------------------------------------------------------------------------
/s/
----------------------------------------------------
SHERAL S PATEL
05/16/2016
HALA H SHAMSUDDIN
05/16/2016

CLINICAL FILING CHECKLIST FOR NDA 208398
NDA Number: 208398 Applicant: Janssen Stamp Date: 19 April 2016

Pharmaceuticals, Inc.
Drug Name: VERMOXTM NDA Type: 505(b)(1) PDUFA Goal Date:
Chewable (mebendazole) 500 mg
19 October 2016
chewable tablets
The Sponsor develops mebendazole 500 mg chewable tablets for donation to the World
Health Organization single-dose mass drug administration programs for soil-transmitted
helminths. The proposed indication is the treatment of single or mixed gastrointestinal
infestations by Trichuris trichiura (whipworm); Ascaris lumbricoides (large
(b) (4)
roundworm); The
mebendazole 500 mg chewable tablet would be administered as a single dose. The
(b)
intended population is adults and pediatrics ( (4) year of age). For individuals who have
difficulty swallowing, water is added to the tablet which changes the tablet into a soft
mass with semi-solid consistency. The Sponsor submits results from an open label,
single-center, single-dose, single arm safety study (GAI3002, n=396) and a double-blind,
randomized, parallel group, placebo-controlled multicenter pediatric study (GAI3003,
n=295) to support their application.
On initial overview of the NDA/BLA application for filing:
Content Parameter Yes No NA Comment

FORMAT/ORGANIZATION/LEGIBILITY
1. Identify the general format that has been used for this X eCTD submission
application, e.g. electronic common technical document
(eCTD).
2. Is the clinical section legible and organized in a manner to x
allow substantive review to begin?
3. Is the clinical section indexed (using a table of contents) x
and paginated in a manner to allow substantive review to
begin?
4. For an electronic submission, is it possible to navigate the x
application in order to allow a substantive review to begin
(e.g., are the bookmarks adequate)?
5. Are all documents submitted in English or are English x
translations provided when necessary?
LABELING
6. Has the applicant submitted a draft prescribing information x
that appears to be consistent with the Physician Labeling
Rule (PLR) regulations and guidances (see
http://www.fda.gov/Drugs/GuidanceComplianceRegulatory
Information/LawsActsandRules/ucm084159 htm
SUMMARIES
7. Has the applicant submitted all the required discipline x
summaries (i.e., Module 2 summaries)?
8. Has the applicant submitted the integrated summary of x Per agreement at pre-
safety (ISS)? NDA meeting 08
March 2016, all safety
information from
various data sources
summarized in
1

Module 2.7.3
Summary of Clinical
Safety.
9. Has the applicant submitted the integrated summary of x Per agreement at pre-
efficacy (ISE)? NDA meeting 08
March 2016, all
efficacy information
for the one pivotal trial
summarized in
Module 2.7.3
Summary of Clinical
Efficacy.
10. Has the applicant submitted a benefit-risk analysis for the x
product?
11. Indicate if the Application is a 505(b)(1) or a 505(b)(2). 505(b)(1)
505(b)(2) Applications
12. If appropriate, what is the relied upon listed drug(s)? x
13. Did the applicant provide a scientific bridge demonstrating x
the relationship between the proposed product and the listed
drug(s)/published literature?
14. Describe the scientific bridge (e.g., BA/BE studies) x
DOSAGE
15. If needed, has the applicant made an appropriate attempt to x 1. GAI1001 Phase1
determine the correct dosage regimen for this product (e.g., Relative
appropriately designed dose-ranging studies)? Bioavailability
Study Healthy adults
(n=18)
2. GAI1002 Phase 1
Food effect Healthy
adults (n=16)
3. GAI3003 Phase 3
Pediatrics subjects,
PK substudy (n=44)
EFFICACY
16. Do there appear to be the requisite number of adequate and x GAI3003: Phase 3
well-controlled studies in the application? randomized, multi-
center, double-blind,
parallel-group,
placebo-controlled
study (n=295)
17. Do all pivotal efficacy studies appear to be adequate and x
well-controlled within current divisional policies (or to the
extent agreed to previously with the applicant by the
Division) for approvability of this product based on
proposed draft labeling?
18. Do the endpoints in the pivotal studies conform to previous x
Agency commitments/agreements? Indicate if there were
not previous Agency agreements regarding
primary/secondary endpoints.
19. Has the application submitted a rationale for assuming the x The drug is intended
applicability of foreign data to U.S. population/practice of to be used for a WHO
medicine in the submission? drug donation program
to treat a neglected
tropical disease, and is
2

not intended to be
marketed for
commercial purposes
in the U.S.
SAFETY
20. Has the applicant presented the safety data in a manner x
consistent with Center guidelines and/or in a manner
previously requested by the Division?
21. Has the applicant submitted adequate information to assess x
the arythmogenic potential of the product (e.g., QT interval
studies, if needed)?
22. Has the applicant presented a safety assessment based on all x
current worldwide knowledge regarding this product?
23. For chronically administered drugs, have an adequate x
number of patients (based on ICH guidelines for exposure 1)
been exposed at the dosage (or dosage range) believed to be
efficacious?
24. For drugs not chronically administered (intermittent or x
short course), have the requisite number of patients been
exposed as requested by the Division?
25. Has the applicant submitted the coding dictionary 2 used for x
mapping investigator verbatim terms to preferred terms?
26. Has the applicant adequately evaluated the safety issues that x
are known to occur with the drugs in the class to which the
new drug belongs?
27. Have narrative summaries been submitted for all deaths and x There were no deaths,
adverse dropouts (and serious adverse events if requested serious adverse events,
by the Division)? or adverse events
leading to
discontinuation in the
Sponsor conducted
clinical studies.
OTHER STUDIES
28. Has the applicant submitted all special studies/data x
requested by the Division during pre-submission
discussions?
29. For Rx-to-OTC switch and direct-to-OTC applications, are x
the necessary consumer behavioral studies included (e.g.,
label comprehension, self selection and/or actual use)?
PEDIATRIC USE
30. Has the applicant submitted the pediatric assessment, or x The Sponsor submits
provided documentation for a waiver and/or deferral? data from a Phase 3
study conducted in
children.
1
For chronically administered drugs, the ICH guidelines recommend 1500 patients overall, 300-600
patients for six months, and 100 patients for one year. These exposures MUST occur at the dose or dose
range believed to be efficacious.
2
The “coding dictionary” consists of a list of all investigator verbatim terms and the preferred terms to
which they were mapped. It is most helpful if this comes in as a SAS transport file so that it can be sorted
as needed; however, if it is submitted as a PDF document, it should be submitted in both directions
(verbatim -> preferred and preferred -> verbatim).
3

PREGNANCY, LACTATION, AND FEMALES AND
MALES OF REPRODUCTIVE POTENTIAL USE
31. For applications with labeling required to be in Pregnancy x
and Lactation Labeling Rule (PLLR) format, has the
applicant submitted a review of the available information
regarding use in pregnant, lactating women, and females
and males of reproductive potential (e.g., published
literature, pharmacovigilance database, pregnancy registry)
in Module 1 (see
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/D
evelopmentResources/Labeling/ucm093307 htm)?
ABUSE LIABILITY
32. If relevant, has the applicant submitted information to x
assess the abuse liability of the product?
FOREIGN STUDIES
33. Has the applicant submitted a rationale for assuming the x The drug is intended
applicability of foreign data in the submission to the U.S. to be used for a WHO
population? drug donation program
to treat a neglected
tropical disease, and is
not intended to be
marketed for
commercial purposes
in the U.S.
DATASETS
34. Has the applicant submitted datasets in a format to allow x
reasonable review of the patient data?
35. Has the applicant submitted datasets in the format agreed to x
previously by the Division?
36. Are all datasets for pivotal efficacy studies available and x
complete for all indications requested?
37. Are all datasets to support the critical safety analyses x In studies GAI3002
available and complete? and GAI3002, adverse
event end dates are
missing in 78% and
33% of records
respectively.
AEOUT (“Outcome of
Adverse Event”)
variable provides
some clarification. In
study 3002, 44 of 45
adverse events that
were missing end
dates had an outcome
of “Not
Recovered/Not
Resolved”. In study
3003, 4 of 10 adverse
events that were
missing end dates had
an outcome of “Not
Recovered/Not
4

Resolved” and 6 of 10
had an outcome of
“Recovering/
Resolving”.
38. For the major derived or composite endpoints, are all of the x
raw data needed to derive these endpoints included?
CASE REPORT FORMS
39. Has the applicant submitted all required Case Report Forms x
in a legible format (deaths, serious adverse events, and
adverse dropouts)?
40. Has the applicant submitted all additional Case Report x
Forms (beyond deaths, serious adverse events, and adverse
drop-outs) as previously requested by the Division?
FINANCIAL DISCLOSURE
41. Has the applicant submitted the required Financial x
Disclosure information?
GOOD CLINICAL PRACTICE
42. Is there a statement of Good Clinical Practice; that all x
clinical studies were conducted under the supervision of an
IRB and with adequate informed consent procedures?
IS THE CLINICAL SECTION OF THE APPLICATION FILEABLE? Yes
If the Application is not fileable from the clinical perspective, state the reasons and provide
comments to be sent to the Applicant.
Not applicable.
Please identify and list any potential review issues to be forwarded to the Applicant for the 74-
day letter.
Information Requests to be communicated to the Sponsor:
1. In studies 3002 and 3003, adverse event end dates are missing in 78% and 33% of records,
respectively. Please clarify and submit an updated dataset for both studies, as needed. The
variable AEENRF (“End Relative to Reference Period”) could be utilized to denote whether an
event was still ongoing at the end of a subject’s participation in a trial or if this information is
unknown.
2. From Office of Scientific Investigations: The clinsite.xpt file that you submitted in NDA 208398
for Study Mebendazolgai3003 failed the quality control check for load to CDER’s Clinical
Investigator Site Selection Tool because you have entered “-1” for all arms at all sites for the
following variables: TRTEFFR, TRTEFFS, SITEEFFE, and SITEEFFS. Please provide a
corrected clinsite.xpt file for Study Mebendazolgai3003.
Sheral S. Patel, M.D. 16 May 2016
Reviewing Medical Officer Date
Hala Shamsuddin, M.D. 16 May 2016

Clinical Team Leader Date
5
---------------------------------------------------------------------------------------------------------
signature.
---------------------------------------------------------------------------------------------------------
/s/
----------------------------------------------------
SHERAL S PATEL
05/16/2016
HALA H SHAMSUDDIN
05/16/2016

Ahahsyba

Uploaded by

Copyright:

Available Formats

Ahahsyba

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Ahahsyba

Uploaded by

Copyright:

Available Formats

CENTER FOR DRUG EVALUATION AND

Adults and pediatrics (greater than 1 year of age)

Adults and pediatrics (greater than 1 year of age)

CDER Clinical Review Template 2015 Edition 1

1 Executive Summary ............................................................................................................... 11

2 Therapeutic Context .............................................................................................................. 17

3 Regulatory Background ......................................................................................................... 18

4 Significant Issues from Other Review Disciplines Pertinent to Clinical Conclusions on

5 Sources of Clinical Data and Review Strategy ....................................................................... 25

CDER Clinical Review Template 2015 Edition 2

6 Review of Relevant Individual Trials Used to Support Efficacy ............................................. 26

7 Integrated Review of Effectiveness ....................................................................................... 33

8 Review of Safety .................................................................................................................... 40

CDER Clinical Review Template 2015 Edition 3

8.4. Safety Results ................................................................................................................. 43

9 Advisory Committee Meeting and Other External Consultations ......................................... 62

10 Labeling Recommendations .................................................................................................. 62

CDER Clinical Review Template 2015 Edition 4

10.3. Nonprescription Labeling ........................................................................................... 65

11 Risk Evaluation and Mitigation Strategies (REMS) ................................................................ 65

12 Postmarketing Requirements and Commitments ................................................................. 65

CDER Clinical Review Template 2015 Edition 5

Table 1: Summary of Key Regulatory Interactions ....................................................................... 19

CDER Clinical Review Template 2015 Edition 6

CDER Clinical Review Template 2015 Edition 7

Figure 1 Overall Study Design for GAI3003................................................................................... 73

CDER Clinical Review Template 2015 Edition 8

CDER Clinical Review Template 2015 Edition 9

NME new molecular entity

CDER Clinical Review Template 2015 Edition 10

2.1. Analysis of Condition

2.2. Analysis of Current Treatment Options

CDER Clinical Review Template 2015 Edition 17

Reference ID: 3995807

3.1.U.S. Regulatory Actions and Marketing History

3.2. Summary of Presubmission/Submission Regulatory Activity

CDER Clinical Review Template 2015 Edition 18

Reference ID: 3995807

Table 1: Summary of Key Regulatory Interactions

Source: NDA 208398, Module 1.2, Reviewer’s Guide, Regulatory History.

3.3. Foreign Regulatory Actions and Marketing History

CDER Clinical Review Template 2015 Edition 19

Reference ID: 3995807

4 Significant Issues from Other Review Disciplines Pertinent to Clinical

4.1. Office of Scientific Investigations (OSI)

4.2. Product Quality

CDER Clinical Review Template 2015 Edition 20

Reference ID: 3995807

4.3. Clinical Microbiology

4.4. Nonclinical Pharmacology/Toxicology

CDER Clinical Review Template 2015 Edition 21

Reference ID: 3995807

4.5. Clinical Pharmacology

Please refer to the Clinical Pharmacology Review by Abhay Joshi, PhD.

4.5.1. Mechanism of Action

A summary of mean mebendazole pharmacokinetic (PK) parameters in Studies GAI3003 and

CDER Clinical Review Template 2015 Edition 22

Reference ID: 3995807

4.5.4 Review Issues Identified by Clinical Pharmacology

1. Higher systemic exposure to mebendazole in young children (age 1 to less than 3